var title_f29_17_29968="Bronchoalveolar ca nodule CT";
var content_f29_17_29968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodule in bronchioloalveolar cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ill-defined nodule in the superior segment of the lingula with a so-called rabbit tail extending towards the anterior aspect of the chest wall and an air-bronchogram. The bronchus extends into the lesion, assuring a high yield for bronchoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29968=[""].join("\n");
var outline_f29_17_29968=null;
var title_f29_17_29969="Influenza pneumonia CXR";
var content_f29_17_29969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Influenza pneumonia with progression over one week",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior chest radiograph (A) shows poorly defined nodular opacities and small areas of consolidation in the right middle and lower lung zones. Chest radiograph one week later (B) demonstrates extensive bilateral consolidation and poorly defined nodular opacities. Also noted are an endotracheal tube and a central venous line. The patient was a 44-year-old man with influenza pneumonia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Muller NL, Franquet T, Lee KS, Silva CIS. Viruses, Mycoplasma, and Chlamydia. In: Imaging of Pulmonary Infections, Lippincott Williams and Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29969=[""].join("\n");
var outline_f29_17_29969=null;
var title_f29_17_29970="Patient information: Immune thrombocytopenia (ITP) (The Basics)";
var content_f29_17_29970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16735\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/5/36948\">",
"         Organs inside the abdomen",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/26/5537\">",
"         Patient information: Complete blood count (CBC) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/50/1826\">",
"         Patient information: Nosebleeds (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/52/21314\">",
"         Patient information: Uterine fibroids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/35/23094\">",
"         Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Immune thrombocytopenia (ITP) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/immune-thrombocytopenia-itp-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6630355\">",
"      <span class=\"h1\">",
"       What is immune thrombocytopenia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Immune thrombocytopenia (ITP) is a bleeding disorder. People with ITP can bruise or bleed much more easily than normal.",
"     </p>",
"     <p>",
"      ITP is caused by a problem with a person&rsquo;s platelets. Platelets are pieces of cells that are normally found in the blood that help blood to clot. People with ITP have fewer platelets than normal.",
"     </p>",
"     <p>",
"      Both adults and children can get ITP, but ITP is more common in children. Children who get ITP usually get it after they have an infection. Doctors do not always know why adults get ITP.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6630370\">",
"      <span class=\"h1\">",
"       What are the symptoms of ITP?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with ITP have no symptoms. When people do have symptoms, they can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bleed easily &ndash; This commonly includes nosebleeds or bleeding from the mouth or gums. Women with ITP can bleed more than usual during their monthly periods.",
"       </li>",
"       <li>",
"        Bruise easily",
"       </li>",
"       <li>",
"        Get a rash of tiny red dots &ndash; The rash is painless and not bumpy. The dots are usually on the feet and ankles.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In children, symptoms usually start suddenly. In adults, symptoms can start slowly or suddenly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6630385\">",
"      <span class=\"h1\">",
"       Is there a test for ITP?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about symptoms and do an exam. He or she will also do blood tests, including a blood test called a &ldquo;complete blood count (CBC).&rdquo; One part of the CBC measures the amount of platelets in the body. This is called the platelet count.",
"     </p>",
"     <p>",
"      To diagnose ITP, the doctor needs to make sure that another condition isn&rsquo;t causing the symptoms. To get more information, doctors sometimes do a test called a bone marrow biopsy. The bone marrow is the tissue inside your bones. It makes all of the blood cells and platelets. During a bone marrow biopsy, a doctor takes a tiny sample of bone marrow. Then another doctor looks at the sample under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6630399\">",
"      <span class=\"h1\">",
"       How is ITP treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for ITP depends on the person&rsquo;s age, platelet count, and symptoms.",
"     </p>",
"     <p>",
"      Children with ITP do not need treatment unless they have a lot of bleeding or have very low platelet counts. For most children, ITP goes away on its own within 6 months. But doctors follow children with ITP closely to make sure the ITP does not get worse or end up needing treatment.",
"     </p>",
"     <p>",
"      Adults with mild ITP do not usually need treatment. But adults with very low platelet counts or bleeding will most likely need treatment.",
"     </p>",
"     <p>",
"      Adults who need treatment are first treated with medicines called steroids. (These medicines are different from the steroids athletes take to build muscle.) Even though steroids can help treat ITP, they can also cause problems of their own. The doctor will talk to you about the possible side effects of steroids.",
"     </p>",
"     <p>",
"      If the ITP doesn&rsquo;t get better with steroids, doctors can use other treatments. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A medicine called &ldquo;intravenous immunoglobulin (IVIG)&rdquo; &ndash; This medicine helps strengthen the body&rsquo;s infection-fighting system. Children who need treatment for their ITP are treated with IVIG before they are treated with steroids.",
"       </li>",
"       <li>",
"        Surgery to remove the spleen &ndash; The spleen is an organ in the body&rsquo;s infection-fighting system that destroys platelets in ITP (",
"        <a class=\"graphic graphic_figure graphicRef61816 \" href=\"UTD.htm?36/5/36948\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Medicines that can help the body make more platelets",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these treatments don&rsquo;t work, other treatments are available.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6630414\">",
"      <span class=\"h1\">",
"       What else might people with ITP need to do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Depending on their platelet count and symptoms, people with ITP might need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Avoid certain sports or activities &ndash; It&rsquo;s very important for children to limit their physical activity and not play certain sports, especially contact sports. That&rsquo;s because children can get hurt by accident. If a person with a very low platelet count gets hurt, he or she can bleed a lot. The doctor will tell you which activities and sports your child should avoid. Adults might also need to limit their activities and sports. People can do their usual sports and activities again when their ITP gets better.",
"       </li>",
"       <li>",
"        Avoid taking certain medicines &ndash; Some medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        , affect blood clotting. Your doctor will let you know which prescription and over-the-counter medicines to avoid.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6630429\">",
"      <span class=\"h1\">",
"       What if I have ITP and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have ITP and want to get pregnant, talk with your doctor or nurse. Most women with ITP have a normal pregnancy and delivery.",
"     </p>",
"     <p>",
"      There is a chance that your baby will have a low platelet count after he or she is born. This usually gets better on its own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6630444\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=see_link\">",
"       Patient information: Nosebleeds (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       Patient information: Uterine fibroids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/26/5537?source=see_link\">",
"       Patient information: Complete blood count (CBC) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"       Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/17/29970?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16735 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29970=[""].join("\n");
var outline_f29_17_29970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630355\">",
"      What is immune thrombocytopenia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630370\">",
"      What are the symptoms of ITP?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630385\">",
"      Is there a test for ITP?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630399\">",
"      How is ITP treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630414\">",
"      What else might people with ITP need to do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630429\">",
"      What if I have ITP and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6630444\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/5/36948\">",
"      Organs inside the abdomen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/26/5537?source=related_link\">",
"      Patient information: Complete blood count (CBC) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/50/1826?source=related_link\">",
"      Patient information: Nosebleeds (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_17_29971="Short tandem repeats";
var content_f29_17_29971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 602px\">",
"   <div class=\"ttl\">",
"    Short tandem repeats",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 582px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Example of a CAG short tandem repeat with genotype 4/6. (B) Slip mispairing: During DNA replication, nascent DNA copy (in purple) slips back one tandem repeat, resulting in duplicate replication of tandem repeat #5. Results in additional copy (total 7) on new strand. (C) Pedigree of Myotonic Dystrophy in three generations with anticipation. Grandmother has 75 tandem repeats at the DMPK gene, no symptoms. Mother has expansion of 530 repeats, with mild symptoms (no respiratory distress) at age 40. Grandson has progressive expansion to 1200 repeats, manifesting with myotonia and respiratory failure at one year of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29971=[""].join("\n");
var outline_f29_17_29971=null;
var title_f29_17_29972="Clinical manifestations of oropharyngeal and esophageal candidiasis";
var content_f29_17_29972=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of oropharyngeal and esophageal candidiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29972/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29972/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29972/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29972/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29972/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29972/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/17/29972/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida infections can involve local mucous membranes (eg, oropharyngitis, esophagitis, and vulvovaginitis) or be focally or systemically invasive.",
"   </p>",
"   <p>",
"    Issues related to oropharyngeal and esophageal candidiasis will be reviewed here. An overview of Candida infections is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .) The treatment of oropharyngeal and esophageal candidiasis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OROPHARYNGEAL CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal candidiasis, or thrush, is a common local infection seen in infants, older adults who wear dentures, patients treated with antibiotics, chemotherapy, or radiation therapy to the head and neck, and those with cellular immune deficiency states, such as AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Patients with xerostomia and those treated with inhaled corticosteroids for asthma or rhinitis are also at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual causative agent is Candida albicans, but other species, including C. glabrata, C. krusei, and C. tropicalis, have been isolated from cases of thrush or esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. These other species are usually present along with C. albicans, which is the probable cause of the symptoms in most patients. However, in highly immunosuppressed AIDS patients, non-albicans species appear to cause disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major forms of oropharyngeal candidiasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pseudomembranous form is the most common and appears as white plaques on the buccal mucosa, palate, tongue, or the oropharynx (",
"      <a class=\"graphic graphic_picture graphicRef75887 \" href=\"UTD.htm?5/12/5312\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The atrophic form, also called denture stomatitis, is the most common form in older adults. It is often found under dentures and is characterized by erythema without plaques (",
"      <a class=\"graphic graphic_picture graphicRef79519 \" href=\"UTD.htm?7/32/7680\">",
"       picture 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with oropharyngeal candidiasis are asymptomatic. The most common symptoms that do occur are a cottony feeling in the mouth, loss of taste, and sometimes pain during eating and swallowing.",
"   </p>",
"   <p>",
"    In addition, immunosuppressed patients with thrush often have concurrent Candida esophagitis or occasionally laryngeal candidiasis. The symptoms of esophageal candidiasis are discussed below; laryngeal candidiasis may be suspected in a patient with evidence of oropharyngeal infection who also complains of hoarseness. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Esophagitis and thrush'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Candida species also cause angular cheilitis, a painful fissuring at the corners of the mouth, while patients with denture stomatitis often have pain when they try to wear their dentures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of oropharyngeal candidiasis is usually suspected clinically and is readily confirmed by scraping the lesions with a tongue depressor and performing a Gram stain or KOH preparation on the scrapings. Budding yeasts with or without pseudohyphae are seen.",
"   </p>",
"   <p>",
"    Although culture of the lesions can be performed, it is rarely indicated unless the disease is recalcitrant or recurrent. Such lesions are likely to be caused by an unusual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    azole-resistant species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL CANDIDIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of esophageal candidiasis is odynophagia or pain on swallowing. Patients usually localize their pain to a discrete retrosternal area.",
"   </p>",
"   <p>",
"    Esophageal candidiasis is most common in HIV-infected patients, in whom it is an AIDS-defining illness and primarily occurs at CD4 cell counts below",
"    <span class=\"nowrap\">",
"     200/microL,",
"    </span>",
"    and in patients with hematologic malignancies. The causative organism is almost always C. albicans although other species are occasionally found [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Invasive candida infections can also be seen in patients with Idiopathic CD4+ lymphocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=see_link\">",
"     \"Idiopathic CD4+ lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Esophagitis and thrush",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophagitis and thrush often occur together in immunosuppressed patients and the presence of thrush may help determine the cause of esophageal symptoms. However, the absence of thrush does not preclude the diagnosis of esophagitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency with which Candida esophagitis occurs in cancer patients with thrush was evaluated in a study of 22 patients with thrush, almost all of whom had a non-hematological cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/7\">",
"       7",
"      </a>",
"      ]. All but one patient also had Candida esophagitis as determined by endoscopy and positive cultures. Ten of these patients had mild esophageal symptoms and the others were asymptomatic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Candida esophagitis is usually made at endoscopy when white mucosal plaque-like lesions are noted (",
"    <a class=\"graphic graphic_picture graphicRef83102 \" href=\"UTD.htm?15/48/16128\">",
"     picture 3",
"    </a>",
"    ). Confirmatory biopsy shows the presence of yeasts and pseudohyphae invading mucosal cells, and culture reveals Candida.",
"   </p>",
"   <p>",
"    An alternative diagnostic approach that has been used in AIDS patients is to treat with systemic antifungal agents on the basis of the patient's history. Odynophagia due to candidiasis should improve within several days.",
"   </p>",
"   <p>",
"    If symptoms do not improve within three to four days, endoscopy and biopsy must be performed since it is likely that a disease other than or in addition to Candida esophagitis is present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The frequency of coinfection was illustrated in a study of 110 HIV-infected patients presenting with esophageal symptoms, 72 of whom were diagnosed with esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the 52 patients with Candida esophagitis, concomitant infection with cytomegalovirus was noted in 22 and with herpes simplex virus in two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5269112\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of esophageal candidiasis includes other infectious etiologies (eg, cytomegalovirus, herpes simplex virus), medication-induced esophagitis, and inflammatory conditions such as eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29972/abstract/10\">",
"     10",
"    </a>",
"    ]. Cytomegalovirus and herpes simplex virus infections are encountered in the HIV-infected patient with advanced AIDS (CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=see_link\">",
"     \"Medication-induced esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6647?source=see_link\">",
"     \"Herpes simplex virus infection of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with odynophagia and dysphagia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6695891\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal candidiasis, or thrush, is a common local infection seen in infants, older adults who wear dentures, AIDS patients, and in patients who have received antibiotics, chemotherapy, or radiation therapy to the head and neck. The usual causative agent is Candida albicans. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Oropharyngeal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of oropharyngeal candidiasis is usually suspected clinically and is readily confirmed through identification of yeast forms on Gram stain or KOH preparation. Cultures are not indicated except in the case of recalcitrant or recurrent cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmark of esophageal candidiasis is odynophagia or pain on swallowing. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal candidiasis is most common in AIDS patients and in patients with hematologic malignancies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Esophageal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Candida esophagitis is usually made through endoscopy with a biopsy of white mucosal plaque-like lesions. Histology demonstrates the presence of yeasts and pseudohyphae invading mucosal cells with a culture confirming Candida. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative diagnostic approach that has been used in AIDS patients is to treat with systemic antifungal agents on the basis of the patient's history. Odynophagia due to candidiasis should improve within several days. Endoscopy can be pursued if empiric therapy does not lead to symptom resolution. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/1\">",
"      Shay K, Truhlar MR, Renner RP. Oropharyngeal candidosis in the older patient. J Am Geriatr Soc 1997; 45:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/2\">",
"      Epstein JB, Freilich MM, Le ND. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol 1993; 76:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/3\">",
"      Iacopino AM, Wathen WF. Oral candidal infection and denture stomatitis: a comprehensive review. J Am Dent Assoc 1992; 123:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/4\">",
"      Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994; 97:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/5\">",
"      Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol 1993; 9:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/6\">",
"      Budtz-J&oslash;rgensen E. Oral mucosal lesions associated with the wearing of removable dentures. J Oral Pathol 1981; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/7\">",
"      Samonis G, Skordilis P, Maraki S, et al. Oropharyngeal candidiasis as a marker for esophageal candidiasis in patients with cancer. Clin Infect Dis 1998; 27:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/8\">",
"      Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/9\">",
"      Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29972/abstract/10\">",
"      Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol 2008; 24:496.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2427 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29972=[""].join("\n");
var outline_f29_17_29972=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6695891\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OROPHARYNGEAL CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ESOPHAGEAL CANDIDIASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Esophagitis and thrush",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5269112\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6695891\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2427|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5312\" title=\"picture 1\">",
"      Oropharyngeal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/32/7680\" title=\"picture 2\">",
"      Candida denture stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/48/16128\" title=\"picture 3\">",
"      Esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=related_link\">",
"      AIDS-related cytomegalovirus gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4707?source=related_link\">",
"      Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6647?source=related_link\">",
"      Herpes simplex virus infection of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30009?source=related_link\">",
"      Idiopathic CD4+ lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_17_29973="Fixed drug eruption multiple";
var content_f29_17_29973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Multiple (generalized) fixed drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Generalized fixed drug eruption is an uncommon variant characterized by multiple and disseminated brown macules or plaques involving the trunk and extremities.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29973=[""].join("\n");
var outline_f29_17_29973=null;
var title_f29_17_29974="Extramammary Pagets disease";
var content_f29_17_29974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramammary Paget disease of the vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29974=[""].join("\n");
var outline_f29_17_29974=null;
var title_f29_17_29975="Perioperative myocardial infarction after noncardiac surgery";
var content_f29_17_29975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative myocardial infarction after noncardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Jonathan B Shammash, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Stephen E Kimmel, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     PJ Devereaux, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Scott Solomon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29975/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/17/29975/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac complications, including cardiac death, nonfatal myocardial infarction (MI), heart failure, or ventricular tachycardia, pose a significant risk to patients undergoing major noncardiac surgery. Of these, perioperative MI is the most common major cardiovascular complication. Issues related to perioperative MI in patients undergoing noncardiac surgery will be reviewed in this topic. Perioperative MI after coronary artery bypass graft surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=see_link&amp;anchor=H3#H3\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Perioperative MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients at increased risk for major cardiac complications, such as MI, can be identified using validated risk indices. The initial preoperative evaluation, the surgery-specific risk, the major indices used for risk stratification, the role of noninvasive testing, the management of cardiac risk in an attempt to reduce morbidity and mortality associated with noncardiac surgery, and issues related to the perioperative evaluation and management of heart failure in patients undergoing noncardiac surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=see_link\">",
"     \"Perioperative heart failure in noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74856543\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of perioperative MI is highly debated. Although supply-demand mismatch (eg, hypertension, hypotension, or tachycardia) has long been thought to explain many perioperative MIs, the evidence to support this explanation is extremely weak. However, plaque rupture may play a central role in many cases. In one angiographic study, nearly 50 percent of patients with perioperative acute coronary syndrome had evidence of plaque rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of perioperative MI in patients undergoing noncardiac surgery varies with the definition of MI used, patient risk (including the type of surgery), monitoring strategy (eg, systematic biomarker monitoring after surgery), and the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to the definition, the incidence of MI is directly related to the sensitivity of the biomarker used. Thus, it is likely that as the sensitivity of cardiac troponin (cTn) assays improve, and the recommended cutoff values that define MI fall, the frequency of identifying perioperative MI will increase. Although it is thought that most of elevations of cTn after noncardiac surgery are due to acute MI, all elevations of cTn should not be assumed to be due to acute MI. Cardiac injury may help to explain some of the heretofore unexplained morbidity associated with noncardiac surgery. &nbsp;",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 1995 review of major published series found that the pooled average rate of perioperative MI ranged from 1.4 percent in unselected patients over age 40 to 6.9 percent in patients selected to undergo preoperative thallium scintigraphy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/3\">",
"       3",
"      </a>",
"      ]. These rates probably represent an underestimate, since the included studies were performed prior to the routine use of troponin assays.",
"     </li>",
"     <li>",
"      The largest published experience in the troponin era comes from over 8000 patients in the randomized POISE trial of perioperative beta blocker therapy in patients at increased cardiovascular risk undergoing noncardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link\">",
"       \"Management of cardiac risk for noncardiac surgery\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In POISE, perioperative MI was defined as an elevated cardiac biomarker or enzyme level (with separate definitions for troponin or CK-MB), and one or more of the following: ischemic symptoms, ECG changes in two contiguous leads (ie, development of pathologic Q waves, ST-segment elevation, ST-segment depression, or T-wave inversion) coronary artery intervention, or evidence of MI on cardiac imaging or autopsy. The incidence of MI in POISE was 5.0 percent at 30 days (4.2 and 5.7 in the beta blocker and placebo groups respectively), and the majority of these MIs (74 percent) occurred within 48 hours of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/5\">",
"       5",
"      </a>",
"      ]. Approximately 65 percent of the patients with MI did not experience ischemic symptoms.",
"      <br/>",
"      <br/>",
"      It is not clear that guideline-recommended cutoff values were used in this study, which relied on local values. Thus, from the biochemical perspective, these data probably underestimate the true frequency of elevated cTn measurements and thus perhaps the true frequency of MI as well.",
"     </li>",
"     <li>",
"      In an analysis of vascular surgery patients, between approximately 3 and 24 percent suffered an MI depending on the cutoff value used for cTn. The assay used was appropriate, but was less sensitive than modern-day assays [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/6\">",
"       6",
"      </a>",
"      ]. The frequency of elevations with the same assay was similar in a study of vascular surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/7\">",
"       7",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In the CARP trial, perioperative MI, defined by a rise in cardiac troponin I (without a requirement for clinical or ECG criteria), was seen in 27 percent of 377 patients with coronary artery disease scheduled to undergo (high-risk) vascular surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of cardiac risk for noncardiac surgery\", section on 'Revascularization versus medical therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An approximation of the incidence of perioperative MI can be made using data from the VISION study of over 15,000 patients in whom troponin T (TnT) was measured serially after (but not before) surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      TnT values of at least 0.02",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      occurred in 11.6 percent of patients. However, troponin elevation alone does not fulfil criteria for the diagnosis of MI. The rate of MI is likely lower, as some of these elevations were likely due to chronic TnT elevation or due to other acute disease process such as pulmonary embolism or sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H4#H4\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute MI'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREDICTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for cardiovascular events (including MI) after noncardiac surgery have been identified and incorporated into validated risk models. The revised Goldman cardiac risk index is the best validated risk index and appears to have greater predictive value than other risk indices (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 1",
"    </a>",
"    ). Risk factors include high-risk surgery, history of ischemic heart disease, heart failure, or cerebrovascular disease, diabetes mellitus requiring treatment with insulin, and preoperative serum creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H19#H19\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Risk Models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CARP trial specifically evaluated predictors of MI in patients with coronary artery disease undergoing elective vascular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/8\">",
"     8",
"    </a>",
"    ]. In this very high-risk group, age greater than 70 years, abdominal aortic surgery, diabetes mellitus, angina and baseline ST-T abnormalities were significantly associated with the development of MI.",
"   </p>",
"   <p>",
"    While high risk surgery, such as abdominal aortic surgery, is associated with the development of perioperative MI, other surgeries such as total hip replacement (THR) and total knee replacement (TKR) also place patients at risk. The magnitude and timing of this risk was evaluated in a retrospective cohort study of 95,227 individuals within the Danish national registries who underwent a primary THR or TKR between 1998 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/10\">",
"     10",
"    </a>",
"    ]. During the first two postoperative weeks, the risk of acute MI was increased compared to matched controls in both groups (adjusted hazard ratio 25.5, 95% CI 17.1-37.9 and 30.9, 95% CI 11.1-85.5, respectively). The risk remained elevated for two to six weeks only in the group with THR. These data add to the growing data, indicating the importance of the immediate post-operative period in patients undergoing orthopedic surgery and likely underestimate the real risk given the lack of aggressive surveillance for the diagnosis of AMI.",
"   </p>",
"   <p>",
"    In the POISE trial, in addition to the Goldman risk predictors, serious bleeding (disabling or requiring &ge;2 units of blood) and an increase in every 10-beats in baseline heart rate were significant independent predictors of perioperative MI (adjusted odds ratio 3.62, 95% CI 2.07-6.36 and 1.29, 95% CI 1.13-1.50, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perioperative hemorrhage as a predictor of MI (or stroke) was also evaluated in a study of 651,775 patients who underwent surgery between 2005 and 2009 at centers participating in the United States National Surgical Quality Improvement Program [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/11\">",
"     11",
"    </a>",
"    ]. Major hemorrhage, defined as bleeding necessitating transfusion of more than four units of packed red blood cells or whole blood, occurred on 0.80 percent. Q-wave MI occurred in 0.24 percent and stroke in 0.20 percent. Hemorrhage was independently associated with MI (hazard ratio [HR] 2.7, 95% CI 2.1-3.4) and stroke (HR 2.3, 95% CI 1.9-3.3) and the risk was related to the severity of bleeding. The risk of MI may be an underestimate due to the use of Q-wave MI as the definition of MI, rather than the use of biomarkers and clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378867\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 Joint Task Force of the European Society of Cardiology, American College of Cardiology Foundation, the American Heart Association, and the World Health Federation",
"    <span class=\"nowrap\">",
"     (ESC/ACCF/AHA/WHF)",
"    </span>",
"    defined acute MI as a clinical event consequent to the death of cardiac myocytes (myocardial necrosis) that is caused by ischemia (but not other etiologies such as myocarditis or trauma) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of noncardiac surgery, MI has occurred if there is a typical rise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis after surgery in conjunction with ischemic symptoms, new or presumably new pathologic Q waves or changes of ischemia on the electrocardiogram, or a new (or presumed new) wall motion abnormality on echocardiography or a fixed defect on radionuclide imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378874\">",
"    <span class=\"h2\">",
"     ECG testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have undergone noncardiac surgery, MI should be suspected when the patient complains of ischemic symptoms. We recommend a 12-lead ECG in",
"    <strong>",
"     all patients with symptoms of myocardial ischemia",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    The issue of when to obtain a screening ECG(s) in asymptomatic patients is unresolved. A minority (14 percent) of patients who have undergone noncardiac surgery have chest pain and only about 50 percent have any sign or symptom that might lead the physician to consider the possibility of myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/2\">",
"     2",
"    </a>",
"    ]. Given the frequent lack of symptoms, we suggest performing electrocardiograms for two and possibly three days in all patients with risk factors for perioperative MI (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link&amp;anchor=H25#H25\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\", section on 'Potential underdiagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the evidence to support the routine performance of a preoperative and a postoperative ECG(s) in high-risk patients is weak compared to that for the use of troponin, some of our experts believe such practice is reasonable. High risk is defined as high-risk surgery with one or more additional risk factors of the revised cardiac risk score or any patients with complications of a possible cardiovascular etiology (",
"    <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378922\">",
"    <span class=\"h2\">",
"     Biomarker testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients with symptoms or electrocardiographic changes suggestive of ischemia or MI, we recommend obtaining serial (two or three) biomarkers. Troponin is the preferred biomarker as CK-MB is less sensitive and less specific in perioperative patients. CK-MB should be measured only if troponin measurement is not available or nondiagnostic (eg, recent, preoperative elevation of troponin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link&amp;anchor=H33#H33\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'Biomarkers after noncardiac surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend routine use of high sensitivity troponin assays until further evidence suggests improved outcomes in this population compared to standard troponin assays. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link&amp;anchor=H2606156726#H2606156726\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'High sensitivity assays'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For",
"    <strong>",
"     all patients at high cardiac risk,",
"    </strong>",
"    we suggest performing serial measurements of the cardiac troponin after surgery. In these patients, the risk of MI is elevated and the likelihood of missing the diagnosis based on symptoms or ECG changes is significant, as was shown in the POISE trial, discussed above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Incidence'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/13\">",
"     13",
"    </a>",
"    ]. High risk is defined as high-risk surgery with one or more additional risk factors of the revised cardiac risk score. In these patients, we suggest obtaining troponin at 6 to 12 hours and days one, two, and three after surgery. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Predictors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In these high cardiac risk patients, our experts are divided as to whether a baseline troponin should be obtained. The principle arguments for doing so are that post-operative elevations may be more properly interpreted and that a baseline measurement might add to current risk prediction models. For example, in a study of 979 relatively high risk individuals, an elevated high sensitivity troponin was associated with an increased mortality (6.9 versus 1.2 percent; p &lt;0.001) and provided independent prognostic information beyond the revised cardiac risk index (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link&amp;anchor=H21#H21\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Revised cardiac risk index'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/14\">",
"     14",
"    </a>",
"    ]. The principle argument against is that patients in whom a preoperative troponin elevation is identified (such as those with chronic elevations) may have their surgery unnecessarily postponed. Until better evidence is available to help with this issue, local practice and clinician preference should guide the choice between obtaining a preoperative troponin or not.",
"   </p>",
"   <p>",
"    Given the worse short-term and long-term outcomes associated with perioperative MI (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Prognosis'",
"    </a>",
"    below) and the fact that symptoms and electrocardiographic changes may lead to the underdetection of perioperative MI, some experts have suggested that somewhat lower-risk patients with risk factors for cardiovascular disease (eg, smoking, hypertension, or dyslipidemia) undergo testing with serial troponin measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/5\">",
"     5",
"    </a>",
"    ]. No observational studies or randomized trials have evaluated outcomes comparing a strategy of biomarker testing in patients without symptoms or ECG changes to a strategy of biomarker testing in these somewhat lower risk individuals. The following represent some of the concerns regarding this latter strategy that lead to our suggestion to not routinely get troponins in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biomarkers may be elevated for reasons other than myocardial ischemia secondary to coronary artery disease. In some patients, they may represent other acute comorbidities (eg, pulmonary embolism in patients undergoing orthopedic surgery) and in some, elevations due to chronic structural heart disease such as left ventricular hypertrophy, chronic kidney disease, or heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=see_link\">",
"       \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In such patients the cost and burdens of recommending long-term therapies such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and statin are unknown when used only for this indication.",
"     </li>",
"     <li>",
"      The level of troponin (or rise in troponin) that should be used to define myocardial infarction in the perioperative setting is uncertain. For instance the role for high sensitivity tests in the care of patients is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link&amp;anchor=H2606156726#H2606156726\">",
"       \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'High sensitivity assays'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those patients in whom an elevated troponin is found, the mechanism (plaque rupture versus a",
"      <span class=\"nowrap\">",
"       supply/demand",
"      </span>",
"      mismatch) might be unclear and thus recommendations for further management might be uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H4#H4\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute MI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The absence of randomized trials that have evaluated outcomes using different intervention strategies in patients who have an increase in perioperative cardiac enzymes.",
"     </li>",
"     <li>",
"      Limitations of those studies providing evidence for a worse prognosis among patients with an elevated troponin. This is particularly true for those who undergo vascular surgery, but data are lacking for other subgroups. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients in whom troponin was not measured or measured at a time that could have missed the clinical event, new pathologic Q waves on the ECG define AMI. For patients in whom the diagnosis remains uncertain after considering symptoms, ECG changes, and the results of biomarker testing, information from additional noninvasive studies (such as a new wall-motion abnormality or fixed defect on echocardiography or radionuclide myocardial perfusion imaging) may be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29578?source=see_link\">",
"     \"Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative myocardial infarction is associated with worse short- and long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/5,6,8,15-18\">",
"     5,6,8,15-18",
"    </a>",
"    ]. It should be kept in mind that mortality rates are directly related to the sensitivity of the tests that led to the documentation of MI. Low sensitivity tests will likely identify larger MIs; these will likely be associated with higher death rates than smaller MIs.",
"   </p>",
"   <p>",
"    The following are representative rates of death after MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In-hospital mortality has been reported from 12 to 25 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/5,15-17\">",
"       5,15-17",
"      </a>",
"      ]. In the POISE trial, the 30-day mortality rate was 11.6 percent in patients with compared to 2.2 percent in those without MI; the risk of nonfatal cardiac arrest, heart failure, and coronary revascularization was also significantly increased [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 15 studies (over 4000 patients) of various types of noncardiac surgery (including high [vascular] and moderate; general, orthopedic, thoracic, gynecologic, and urologic) with follow-up ranging between 3 and 48 months, an elevation of either troponin (either I or T) or CK-MB was associated with a significantly increased risk of all-cause mortality (adjusted odds ratio 3.4, 95% CI 2.2-5.2 and 2.5, 95% CI 1.5-4.0, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/19\">",
"       19",
"      </a>",
"      ]. In the 10 studies that assessed intermediate-term (&lt;12 months) mortality, the odds ratio was 6.7 (95% CI 4.1-10.9). &nbsp;",
"     </li>",
"     <li>",
"      The relationship between peak postoperative (fourth generation) troponin levels and 30-day mortality was evaluated in the VISION study, a prospective cohort study of 15,133 patients 45 years of age or older who required at least an overnight hospital admission after noncardiac surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/9\">",
"       9",
"      </a>",
"      ]. In VISION, participants had troponin T (TnT) measured (using a fourth generation assay) 6 to 12 hours postoperatively and on the first, second, and third days after surgery. As preoperative troponin was not measured and as clinical events such as the presence of ischemic chest pain or electrocardiographic changes suggestive of myocardial ischemia were not reported, this initial VISION publication did not directly associate perioperative MI to mortality. Troponin elevation alone does not fulfil criteria for the diagnosis of MI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In VISION, the overall 30-day mortality rate was 1.9 percent; about one-quarter of deaths occurred after hospital discharge. Multivariable analysis demonstrated that peak TnT values of at least 0.02",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      which occurred in 11.6 percent of patients, were associated with significantly higher 30-day mortality compared with the reference group (Tn &le;0.01",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      Patients with peak TnT values of 0.01",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or less, 0.02, 0.03 to 0.29, and 0.30 or greater had 30-day mortality rates of 1.0, 4.0, 9.3, and 16.9 percent, respectively.",
"      <span class=\"nowrap\">",
"       Urgent/emergent",
"      </span>",
"      surgery was the strongest preoperative predictor of mortality; however, the strongest perioperative predictor of death was an elevated troponin measurement after surgery. A cardiovascular cause of death was present in 45 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to increased mortality, nonfatal perioperative MI is an important independent risk factor for a nonfatal acute coronary syndrome or progressive angina requiring revascularization later after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29975/abstract/2,6,8,18\">",
"     2,6,8,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies suggest that elevations of cTnI not only define short-term risk but also are indicative of serious underlying disease with longer-term significance. Despite the clear relationship between perioperative MI and prognosis, the benefit from screening all patients for perioperative MI has not been established. Our recommendations for screening are presented above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnosis and screening'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Strategies to prevent MI before surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378049\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients who sustain an MI in the perioperative period, we suggest that patients be managed in a manner similar to that for the general population of individuals with MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We make the following specific suggestions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statin and beta-blocker therapies should be initiated unless contraindicated. Some experts consider waiting two or three days prior to initiating beta blocker (in patients not already on beta blockers) in an attempt to avoid hypotension during this period. Patients, such as those with recurrent ischemia or atrial fibrillation with a rapid response, may require initiation of beta blocker therapy sooner than this time frame.",
"     </li>",
"     <li>",
"      Antithrombotic therapy, including oral antiplatelet therapy and intravenous anticoagulant and antiplatelet therapy are used in many patients with spontaneous myocardial infarction, which is often due to a plaque-rupture event. However, in patients who have undergone surgery recently, the risk of bleeding with these agents may be significantly increased. As some of these patients may have suffered an MI due to abnormalities in supply-demand balance, it is unclear that these patients need the aggressive antithrombotic therapy and early intervention that patients with plaque rupture require. The decision to start one or more of them should be made only after careful consideration of the risks and benefits.",
"     </li>",
"     <li>",
"      Monitoring in an intensive care unit for at least 24 hours is advised, particularly if the diagnosis is made within the first 24 hours of surgery.",
"     </li>",
"     <li>",
"      An echocardiogram should be obtained in most patients.",
"     </li>",
"     <li>",
"      Further risk stratification for the extent of coronary artery disease should be performed when the patient&rsquo;s clinical condition allows.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocardial infarction (MI) in patients undergoing noncardiac surgery is defined as a rise in biomarker (either troponin or CK-MB) in association with either suggestive symptoms or electrocardiographic changes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perioperative MI is not uncommon and occurs with increasing frequency as the number of identified risk factors increases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both short- and long-term survival are decreased in patients who have sustained a perioperative MI. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We believe it is reasonable to treat patients with perioperative MI similar to patients with MI in the general population. However, the decision to start one or more antithrombotic agents should be made only after careful consideration of the risks (principally bleeding) and benefits. (See",
"      <a class=\"local\" href=\"#H378049\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend measurement of cardiac troponin for the following patients (see",
"      <a class=\"local\" href=\"#H378922\">",
"       'Biomarker testing'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All those with symptoms or electrocardiographic changes suggestive of ischemia or MI (two or three serial biomarkers).",
"     </li>",
"     <li>",
"      All those at high cardiac risk (at 6 to 12 hours, and days 1, 2, and 3 after surgery). High risk is defined as high-risk surgery with one or more additional risk factors of the revised cardiac risk score (",
"      <a class=\"graphic graphic_table graphicRef57075 \" href=\"UTD.htm?42/4/43083\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While less sensitive and less validated than troponin testing, we recommend obtaining a 12-lead electrocardiogram in the perioperative period for the following patients (see",
"      <a class=\"local\" href=\"#H378049\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients with symptoms of myocardial ischemia.",
"     </li>",
"     <li>",
"      All patients with risk factors for perioperative MI (baseline and daily for two, and possibly, three days).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/1\">",
"      Gualandro DM, Campos CA, Calderaro D, et al. Coronary plaque rupture in patients with myocardial infarction after noncardiac surgery: frequent and dangerous. Atherosclerosis 2012; 222:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/2\">",
"      Devereaux PJ, Goldman L, Yusuf S, et al. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ 2005; 173:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/3\">",
"      Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. N Engl J Med 1995; 333:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/4\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/5\">",
"      Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 2011; 154:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/6\">",
"      Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol 2003; 42:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/7\">",
"      Bursi F, Babuin L, Barbieri A, et al. Vascular surgery patients: perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J 2005; 26:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/8\">",
"      McFalls EO, Ward HB, Moritz TE, et al. Predictors and outcomes of a perioperative myocardial infarction following elective vascular surgery in patients with documented coronary artery disease: results of the CARP trial. Eur Heart J 2008; 29:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/9\">",
"      Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators, Devereaux PJ, Chan MT, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012; 307:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/10\">",
"      Lalmohamed A, Vestergaard P, Klop C, et al. Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med 2012; 172:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/11\">",
"      Kamel H, Johnston SC, Kirkham JC, et al. Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction. Circulation 2012; 126:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/12\">",
"      Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/13\">",
"      Mohler ER 3rd, Mantha S, Miller AB, et al. Should troponin and creatinine kinase be routinely measured after vascular surgery? Vasc Med 2007; 12:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/14\">",
"      Weber M, Luchner A, Manfred S, et al. Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. Eur Heart J 2013; 34:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/15\">",
"      Badner NH, Knill RL, Brown JE, et al. Myocardial infarction after noncardiac surgery. Anesthesiology 1998; 88:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/16\">",
"      Shah KB, Kleinman BS, Sami H, et al. Reevaluation of perioperative myocardial infarction in patients with prior myocardial infarction undergoing noncardiac operations. Anesth Analg 1990; 71:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/17\">",
"      Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/18\">",
"      Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002; 106:2366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29975/abstract/19\">",
"      Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: a systematic review and meta-analysis. Anesthesiology 2011; 114:796.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 69 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29975=[""].join("\n");
var outline_f29_17_29975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74856543\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREDICTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378867\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378874\">",
"      ECG testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378922\">",
"      Biomarker testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H378049\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/69\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/69|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/4/43083\" title=\"table 1\">",
"      Revised cardiac risk index",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29578?source=related_link\">",
"      Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_17_29976="Approach to the adult with acute diarrhea in developing countries";
var content_f29_17_29976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with acute diarrhea in developing countries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Regina LaRocque, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29976/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/17/29976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1169885057\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://www.searo.who.int/LinkFiles/Reports_GBD_report_2004update_full.pdf\">",
"     World Health Organization (WHO) 2004 Global Burden of Disease update",
"    </a>",
"    estimated that there are approximately 4.6 billion episodes of diarrheal illness every year worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/1\">",
"     1",
"    </a>",
"    ]. According to this report, diarrheal diseases represent one of the five leading causes of death worldwide and are the second leading cause of death in children under five years of age (behind acute respiratory infections). Most cases of diarrhea are associated with contaminated food and water sources, and around 2.4 billion people globally have no access to basic sanitation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO provides guidelines for the management of diarrheal illness in developing countries in \"The Treatment of Diarrhea: A Manual for Physicians and Other Senior Health Workers\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/3\">",
"     3",
"    </a>",
"    ]. Specific WHO guidelines for the management of epidemic shigellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/4\">",
"     4",
"    </a>",
"    ] and cholera [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/5\">",
"     5",
"    </a>",
"    ] are also available. The recommendations in this topic are consistent with those guidelines.",
"   </p>",
"   <p>",
"    This topic reviews the clinical assessment, treatment, and prevention of acute diarrhea, including watery diarrhea and dysentery, in adults in developing countries.",
"   </p>",
"   <p>",
"    The clinical assessment and management of children with acute diarrhea in developing countries and of individuals with diarrhea in resource-rich settings are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5625?source=see_link\">",
"     \"Approach to the child with acute diarrhea in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=see_link\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link\">",
"     \"Overview of the causes of chronic diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77501562\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is defined as the passage of loose or watery stools, typically at least three times in a 24-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/6\">",
"     6",
"    </a>",
"    ]. Acute diarrhea is defined as diarrhea of &le;14 days in duration, in contrast to persistent (&gt;14 days and &le;30 days) or chronic (&gt;30 days) diarrhea. Invasive diarrhea, or dysentery, is defined as diarrhea with visible blood, in contrast to watery diarrhea. Dysentery is commonly associated with fever and abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885064\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885166\">",
"    <span class=\"h2\">",
"     Worldwide incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the available data for younger children, incidence of diarrheal disease in older children and adults has not been systematically calculated for many countries. In a systematic review of 23 prospective studies of diarrheal disease in individuals older than five years, estimated diarrhea morbidity rates ranged from 30 episodes per 100 person-years among adults in southeast Asia to 88 episodes per 100 person-years in the eastern Mediterranean region; rates had not changed substantially over 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/7\">",
"     7",
"    </a>",
"    ]. Incidence in Africa was not evaluated in any of the studies included in the review.",
"   </p>",
"   <p>",
"    Diarrheal illness occurs at a baseline frequency in developing countries, superimposed with epidemic cases of diarrhea, either dysentery or watery diarrhea. Epidemics are generally due to Shigella dysenteriae serotype 1 (Sd1) and Vibrio cholerae. Major outbreaks due to Sd1 have occurred in Africa, South Asia, and Central America. In 1994, an explosive outbreak among Rwandan refugees in Zaire caused approximately 20,000 deaths during the first month alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/8\">",
"     8",
"    </a>",
"    ]. Epidemics due to V. cholerae have occurred throughout Africa, Asia, the Middle East, South and Central America, and the Caribbean [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/9\">",
"     9",
"    </a>",
"    ]. Cholera outbreaks can be particularly extensive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H3618915#H3618915\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\", section on 'Developing countries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outbreaks due to Escherichia coli O157:H7, which is occasionally responsible for diarrheal epidemics in the developing world, have been reported in Swaziland in 1992, as well as in Cameroon from 1997 to 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=see_link&amp;anchor=H4450891#H4450891\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77501856\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885173\">",
"    <span class=\"h3\">",
"     Crowding and poor sanitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals in refugee camps and unplanned urban settlements, with limited access to water and sanitation facilities, are at particular risk of diarrheal epidemics. Contaminated food and water play an important role in such epidemics. Direct contact with an infected individual may also contribute to the spread of epidemic dysentery due to S. dysenteriae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885180\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection is prevalent in many areas of the developing world where acute diarrheal diseases occur, and diarrhea-related morbidity and mortality may be increased in these individuals. Several enteric bacteria, such as Campylobacter, Salmonella, Shigella, enteroaggregative E. coli, and Vibrio species, occur with increased frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity in individuals with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Coinfection with multiple pathogens may also occur. Nontyphoidal salmonellosis is a particular concern in HIV-infected individuals, who have a higher risk for recurrent or extraintestinal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31542?source=see_link\">",
"     \"Nontyphoidal Salmonella bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although individuals with HIV are susceptible to a broader variety of enteric pathogens, common causes of infectious diarrhea should be considered first among adults with acute diarrhea in the developing world. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885073\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of bacteria, viruses, and parasites can cause acute diarrhea in the developing world. Relatively new microbiologic causes of diarrhea have also been identified over time, including Norwalk-like viruses, enteroaggregative E. coli, and enterotoxigenic Bacteroides fragilis.",
"   </p>",
"   <p>",
"    Information about the host, the type of diarrhea, and the clinical setting may be useful in indicating possible pathogens. However, a microbiologic diagnosis is not made in the majority of clinical cases in developing countries and is not routinely required for clinical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885231\">",
"    <span class=\"h2\">",
"     Epidemic diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. dysenteriae and V. cholerae are the most common organisms associated with epidemic diarrhea.",
"   </p>",
"   <p>",
"    Four species of Shigella cause bloody diarrhea; they are distinguished serologically as S. dysenteriae, S. flexneri, S. boydii, and S. sonnei (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\"",
"    </a>",
"    ). Of those, S. dysenteriae serotype 1 (Sd1) is uniquely responsible for epidemic dysentery. &nbsp;",
"   </p>",
"   <p>",
"    Four important features account for the association between Sd1 and large, regional epidemics of dysentery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It produces a potent cytotoxin (Shiga toxin) that causes patchy destruction of the colonic epithelium.",
"     </li>",
"     <li>",
"      The low infective dose (10 to 100 organisms) facilitates person-to-person spread of infection.",
"     </li>",
"     <li>",
"      Illness due to Sd1 is more severe and more prolonged than illness due to other species of Shigella.",
"     </li>",
"     <li>",
"      Resistance to antimicrobials is more common than in other species of Shigella.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cholera is a secretory diarrheal disease caused by enterotoxin-producing strains of V. cholerae. More than 200 serogroups of V. cholerae have been identified to date, but historically, the O1 serogroup has caused the vast majority of disease. The O139 serogroup emerged as a cause of disease in 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/17\">",
"     17",
"    </a>",
"    ], but has remained limited to a few countries in Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, enterohemorrhagic E. coli may cause epidemics of bloody diarrhea, similar to Sd1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885262\">",
"    <span class=\"h2\">",
"     Acute watery diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of pathogens can cause acute watery diarrhea in the developing world (",
"    <a class=\"graphic graphic_table graphicRef86525 \" href=\"UTD.htm?26/11/26812\">",
"     table 1",
"    </a>",
"    ). In a non-epidemic situation, enterotoxigenic E. coli is the most common cause. In addition to causing epidemic disease, Vibrio cholerae is endemic in approximately 50 countries in Asia, Africa, and Central and South America, where predictable seasonal outbreaks occur. Norovirus, Campylobacter species, nontyphoidal Salmonellae, Aeromonas species, and enteroaggregative E. coli are other pathogens that can cause acute watery diarrhea in the developing world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885269\">",
"    <span class=\"h2\">",
"     Acute bloody diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, Shigella species, particularly S. flexneri, are the most important causes of acute bloody diarrhea. Other causes in the developing world include Campylobacter jejuni, enteroinvasive and enterohemorrhagic E. coli, nontyphoidal Salmonella species, Entamoeba histolytica, and Schistosoma mansoni (",
"    <a class=\"graphic graphic_table graphicRef86525 \" href=\"UTD.htm?26/11/26812\">",
"     table 1",
"    </a>",
"    ). &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77501965\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As above, diarrhea is the passage of loose stools, typically at least three times in a 24-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/6\">",
"     6",
"    </a>",
"    ]. Watery diarrhea is characteristically nonbloody, whereas dysentery is defined as diarrhea with visible blood. &nbsp;",
"   </p>",
"   <p>",
"    In an outbreak setting, these clinical features can be used to distinguish cholera (watery diarrhea) from epidemic dysentery due to S. dysenteriae serotype 1 (Sd1), as the distinction has therapeutic and public health implications (",
"    <a class=\"graphic graphic_table graphicRef86522 \" href=\"UTD.htm?19/28/19916\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H1169885312\">",
"     'Antibiotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A &ldquo;rice-water&rdquo; appearance of stool flecked with mucous is suggestive of cholera (",
"    <a class=\"graphic graphic_picture graphicRef52564 \" href=\"UTD.htm?41/36/42561\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, diarrhea caused by V. cholerae may present very suddenly with vomiting and abdominal cramping but not frank pain or tenesmus. Fever is uncommon in cholera. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, shigellosis is typically characterized by the frequent passage of small liquid stools that contain visible blood, with or without mucous [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/18\">",
"     18",
"    </a>",
"    ]. Abdominal cramps and tenesmus are common, along with fever and anorexia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, within these two categories of diarrhea, the specific infectious causes cannot be determined based on signs or symptoms. The clinical illnesses caused by the various pathogens associated with watery diarrhea are typically indistinguishable. Similarly, Shigellosis cannot be distinguished reliably from other causes of bloody diarrhea on the basis of clinical features alone, nor can illness caused by Sd1 be distinguished with certainty from that caused by other Shigella species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10153248\">",
"    <span class=\"h2\">",
"     Complications of acute diarrheal diseases in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequelae of severe volume depletion are the most important systemic complications of acute diarrheal disease in adults. Various clinical features can be helpful in determining the severity of hypovolemia, with sunken eyes, dry mouth and tongue, thirst, and decreased skin turgor seen with moderate hypovolemia and decreased consciousness, inability to drink, and a weak pulse seen in more severe stages.",
"   </p>",
"   <p>",
"    Hypovolemia and accompanying electrolyte imbalances are the most important complications of cholera. In contrast, severe volume depletion does not usually occur with Shigella infection.",
"   </p>",
"   <p>",
"    Other systemic complications of diarrheal illness may occur in adults (",
"    <a class=\"graphic graphic_table graphicRef86528 \" href=\"UTD.htm?27/4/27723\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31542?source=see_link\">",
"       \"Nontyphoidal Salmonella bacteremia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemolytic-uremic syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Hemolytic-uremic syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Hemolytic-uremic syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Guillain-Barr&eacute; syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"       \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\", section on 'Guillain-Barr&eacute; syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reactive arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link&amp;anchor=H4#H4\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serious complications may occur with Shigella infection, including sepsis, seizures, rectal prolapse, toxic megacolon, and the hemolytic-uremic syndrome.",
"   </p>",
"   <p>",
"    Among HIV-infected individuals in the developing world, bacteremia with non-typhoidal S. enterica is a particular concern [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502176\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute diarrhea in adults in the developing world is most frequently caused by an infectious agent. In addition to the pathogens above, diarrhea may also occur in the context of other systemic infections, such as influenza, HIV infection, dengue fever, and malaria. Non-infectious etiologies of diarrhea are often missed and should be considered in patients with repeated episodes of self-limiting or acute diarrhea or chronic diarrhea. Such causes include inflammatory bowel disease and malabsorptive syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885082\">",
"    <span class=\"h1\">",
"     CLINICAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of adults with acute diarrhea should include a careful history and physical exam in order to assess the type of diarrhea and the severity of hypovolemia.",
"   </p>",
"   <p>",
"    Based on the appearance of the stool, diarrhea can be classified as watery or bloody.",
"   </p>",
"   <p>",
"    The physical exam should focus on characterizing the degree of volume depletion (",
"    <a class=\"graphic graphic_table graphicRef74796 \" href=\"UTD.htm?12/55/13180\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early hypovolemia &ndash; signs and symptoms may be absent",
"     </li>",
"     <li>",
"      Moderate hypovolemia &ndash; thirst, restless or irritable behavior, decreased skin turgor, sunken eyes",
"     </li>",
"     <li>",
"      Severe hypovolemia &ndash; diminished consciousness, lack of urine output, cool moist extremities, rapid and feeble pulse, low or undetectable blood pressure, peripheral cyanosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory studies are not typically needed. However, when available, certain diagnostic tests can help to identify the microbial etiology, which is especially useful in an epidemic situation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine microscopy of fresh stool is inexpensive and can identify the presence of numerous fecal leukocytes, suggesting an invasive bacterial infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to the adult with acute diarrhea in developed countries\", section on 'Fecal leukocytes and occult blood'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microscopic evidence of Entamoeba trophozoites containing red blood cells provides sufficient basis for treating for amoebic dysentery instead of shigellosis (",
"      <a class=\"graphic graphic_picture graphicRef57615 \" href=\"UTD.htm?22/53/23390\">",
"       picture 2",
"      </a>",
"      ). Notably, finding cysts or trophozoites without red blood cells in a bloody stool does not indicate that Entamoeba is the cause of illness, since asymptomatic infection is frequent among healthy persons in developing countries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"       \"Intestinal Entamoeba histolytica amebiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cholera can be diagnosed using dark field microscopy, in which motile Vibrios appear as \"shooting stars.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum electrolyte and glucose testing is not routinely required for the treatment of an adult patient with an uncomplicated case of acute watery diarrhea. Testing may be considered in patients with ileus, confusion, or seizure, or in those with no urine output in response to fluid replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885090\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate fluid and electrolyte replacement and maintenance are essential to the management of diarrheal illness. Antimicrobials are not routinely warranted, but they do play a role in the treatment of bloody diarrhea and during diarrheal outbreaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885319\">",
"    <span class=\"h2\">",
"     Rehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid management, including the type and quantity of fluids to administer, in an adult patient with diarrhea depends on the level of volume depletion (",
"    <a class=\"graphic graphic_algorithm graphicRef86529 \" href=\"UTD.htm?23/39/24191\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502056\">",
"    <span class=\"h3\">",
"     None to moderate hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the vast majority of cases, volume depletion from acute diarrhea of any etiology, except when it is severe, can be effectively treated with oral rehydration salts (ORS) (",
"    <a class=\"graphic graphic_algorithm graphicRef86529 \" href=\"UTD.htm?23/39/24191\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/21\">",
"     21",
"    </a>",
"    ]. An improved, reduced osmolarity ORS solution, containing 75",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of sodium and 75",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of glucose (",
"    <a class=\"graphic graphic_table graphicRef86526 \" href=\"UTD.htm?1/15/1275\">",
"     table 5",
"    </a>",
"    ), is officially recommended by the World Health Organization (WHO) and The United Nations Children&rsquo;s Fund (UNICEF). This reduced osmolarity solution reduces the need for supplemental IV fluid therapy by 33 percent compared with the previous standard WHO ORS solution [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of glucose polymers (primarily rice, but also wheat, sorghum, or maize) in ORS has been shown to decrease mean 24 hour stool output in adults with cholera when compared to the traditional, high osmolarity ORS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, the preparation of such polymer-based ORS is more tedious than that of traditional ORS, and further data are needed to assess its efficacy compared with the reduced osmolarity ORS solution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502070\">",
"    <span class=\"h3\">",
"     Severe hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with severe hypovolemia should receive intravenous fluids (",
"    <a class=\"graphic graphic_algorithm graphicRef86529 \" href=\"UTD.htm?23/39/24191\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/3\">",
"     3",
"    </a>",
"    ]. Ringer&rsquo;s lactate or Ringer&rsquo;s lactate with 5 percent dextrose are preferred, but normal saline can also be used. Normal saline is less preferable because it does not contain potassium to replace losses nor a base to correct acidosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885312\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502155\">",
"    <span class=\"h3\">",
"     Watery diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy is not typically indicated for the treatment of acute watery diarrhea in adults in the developing world, as most cases resolve spontaneously. In trials of adults from the developed world with travelers&rsquo; diarrhea, appropriate antibiotics can decrease the duration of symptoms for certain bacterial etiologies by one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. However, in the developing world, this possible modest benefit is outweighed by the risk of adverse effects, the risk of selection of drug resistance, and the impracticality of selection and distribution of antimicrobials for the number of individuals affected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important exception is the treatment of severe cholera in outbreak settings, for which antibiotics can decrease the duration of illness and the volume of fluid losses, thus simplifying patient management during a complex emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/9\">",
"     9",
"    </a>",
"    ]. Reports of resistance in V. cholerae are increasing; data on local susceptibility should therefore be used to guide treatment choices. Antibiotic treatment of cholera is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef71548 \" href=\"UTD.htm?20/46/21228\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77502169\">",
"    <span class=\"h3\">",
"     Dysentery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the treatment of watery diarrhea, adults with bloody diarrhea should be treated promptly with an antimicrobial that is effective against Shigella. In several trials of patients with dysentery, antibiotics reduced the duration of diarrhea and fever in infections caused by Shigella, which is the most common cause of dysentery in the developing world and can otherwise be associated with severe complications [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/4,30\">",
"     4,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment should be particularly targeted at those with higher risks of complications, including individuals with AIDS and the elderly. The choice of antimicrobial should be based on recent susceptibility data from Shigella strains isolated in the area, if available. Because resistance of Shigella to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and nalidixic acid has become widespread in the developing world,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    is now the drug of choice for all patients with acute bloody diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/4\">",
"     4",
"    </a>",
"    ]. Antibiotic therapy for shigellosis is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_table graphicRef86527 \" href=\"UTD.htm?26/10/26795\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of Shigella infection in adults\", section on 'Antibiotic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If amebic dysentery due to E. histolytica is suspected based on stool microscopy,&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (500 to 750 mg orally three times daily for 7 to 10 days) is the usual treatment (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    ). A diagnosis of amebic dysentery should also be considered in a patient who does not respond within two days to empiric treatment for shigellosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885338\">",
"    <span class=\"h3\">",
"     Antimicrobial resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial resistance in enteric pathogens in the developing world is increasingly common [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and is, in part, due to the misuse and overuse of antibiotics in the treatment of diarrheal diseases. Multidrug resistance has been identified in nontyphoidal Salmonella, Shigella spp, and V. cholerae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]; resistance complicates the antibiotic treatment of severely ill patients and the management of diarrheal outbreaks. A recent study of diarrheal stool samples in rural western Kenya determined that most persons had been treated with an antimicrobial to which their isolate was resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/38\">",
"     38",
"    </a>",
"    ]. When possible, the selection of antimicrobial treatment for acute diarrheal diseases should therefore be based on recent susceptibility testing of strains from the area. Restriction of public retail availability of antimicrobial agents may also play a role in containing resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H8785158#H8785158\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prevention of Shigella infection in adults\", section on 'Antimicrobial resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885345\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The continuous provision of nutritious food is important for all patients with diarrhea. Small meals can be provided frequently, as soon as the patient is able to tolerate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885106\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute diarrheal diseases can be prevented with a variety of measures focused on preventing the spread of organisms from person to person and within the community [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hand washing with soap",
"     </li>",
"     <li>",
"      Ensuring the availability of safe drinking water",
"     </li>",
"     <li>",
"      Appropriate disposal of human waste",
"     </li>",
"     <li>",
"      Breastfeeding of infants and young children",
"     </li>",
"     <li>",
"      Safe handling and processing of food",
"     </li>",
"     <li>",
"      Control of flies (particularly for Sd1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several vaccines for V. cholerae have been developed, but none are in widespread use in the developing world at the present time. However, the World Health Organization has recently recommended that cholera vaccination should be implemented in endemic areas and in areas at risk for outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29976/abstract/41\">",
"     41",
"    </a>",
"    ]. Candidate vaccines for shigellosis are undergoing testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169885113\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrheal illness in the developing world is extremely common, but incidence rates for adults have not been systematically calculated. Cases of diarrhea can occur as baseline endemic disease or in the setting of epidemics. Poor sanitation is a major risk factor for the prevalence of diarrhea in both endemic and epidemic forms. (See",
"      <a class=\"local\" href=\"#H1169885064\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple pathogens can cause watery and bloody diarrhea (dysentery) (",
"      <a class=\"graphic graphic_table graphicRef86525 \" href=\"UTD.htm?26/11/26812\">",
"       table 1",
"      </a>",
"      ). Shigella dysenteriae serotype 1 and Vibrio cholerae are the most important causes of diarrheal epidemics, and certain clinical features can distinguish between the two (",
"      <a class=\"graphic graphic_table graphicRef86522 \" href=\"UTD.htm?19/28/19916\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1169885073\">",
"       'Microbiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H77501965\">",
"       'Clinical features'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Severe volume depletion is the most important complication of acute diarrheal illness in adults. However, several other systemic complications can occur, including bacteremia, hemolytic-uremic syndrome, Guillain-Barr&eacute; syndrome, and reactive arthritis. (See",
"      <a class=\"local\" href=\"#H10153248\">",
"       'Complications of acute diarrheal diseases in adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical assessment of the adult patient with acute diarrhea should focus on characterizing the type of diarrhea (watery versus bloody) and the degree of volume depletion. A microbiologic diagnosis is not needed in the majority of clinical cases of adults with diarrheal illness in developing countries. (See",
"      <a class=\"local\" href=\"#H1169885082\">",
"       'Clinical assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate fluid and electrolyte replacement and maintenance are essential to the management of all diarrheal illnesses (",
"      <a class=\"graphic graphic_algorithm graphicRef86529 \" href=\"UTD.htm?23/39/24191\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef86526 \" href=\"UTD.htm?1/15/1275\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1169885319\">",
"       'Rehydration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with acute watery diarrhea, we suggest not routinely administering empiric antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, one exception is in the epidemic setting, in which antibiotic therapy against cholera can decrease the duration of illness and the volume of fluid losses and thus simplify patient management during a complex emergency (",
"      <a class=\"graphic graphic_table graphicRef71548 \" href=\"UTD.htm?20/46/21228\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H77502155\">",
"       'Watery diarrhea'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of Vibrio cholerae infection\", section on 'Antimicrobial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For adults with bloody diarrhea, we suggest prompt empiric antibiotic treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An antimicrobial that is effective against Shigella should be used (",
"      <a class=\"graphic graphic_table graphicRef86527 \" href=\"UTD.htm?26/10/26795\">",
"       table 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H77502169\">",
"       'Dysentery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment and prevention of Shigella infection in adults\", section on 'Antibiotic treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. The Global Burden of Disease: 2004 update. Geneva, Switzerland: World Health Organization, 2008.",
"    </li>",
"    <li>",
"     World Health Organization. Water Sanitation and Health. Geneva, Switzerland: World Health Organization, 2004.",
"    </li>",
"    <li>",
"     World Health Organization. The treatment of diarrhoea, a manual for physicians and other senior health workers. -- 4th revision. Geneva, Switzerland: World Health Organization, 2005.",
"    </li>",
"    <li>",
"     Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva, Switzerland: World Health Organization, 2005.",
"    </li>",
"    <li>",
"     Cholera outbreak: assessing the outbreak response and improving preparedness. Geneva, Switzerland: World Health Organization, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/6\">",
"      Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/7\">",
"      Walker CL, Black RE. Diarrhoea morbidity and mortality in older children, adolescents, and adults. Epidemiol Infect 2010; 138:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/8\">",
"      Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994? Goma Epidemiology Group. Lancet 1995; 345:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/9\">",
"      Harris JB, LaRocque RC, Qadri F, et al. Cholera. Lancet 2012; 379:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/10\">",
"      Cholera, Zimbabwe--update. Wkly Epidemiol Rec 2009; 84:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/11\">",
"      Effler E, Isa&auml;cson M, Arntzen L, et al. Factors contributing to the emergence of Escherichia coli O157 in Africa. Emerg Infect Dis 2001; 7:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/12\">",
"      Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/13\">",
"      Wanke CA, Mayer H, Weber R, et al. Enteroaggregative Escherichia coli as a potential cause of diarrheal disease in adults infected with human immunodeficiency virus. J Infect Dis 1998; 178:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/14\">",
"      Niyogi SK. Shigellosis. J Microbiol 2005; 43:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/15\">",
"      Ndlovu N, Tarupiwa A, Mudzori JT. Antimicrobial resistence of Shigella species isolated during 2004 and 2005 from selected sites in Zimbabwe. Cent Afr J Med 2006; 52:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/16\">",
"      Talukder KA, Khajanchi BK, Islam MA, et al. The emerging strains of Shigella dysenteriae type 2 in Bangladesh are clonal. Epidemiol Infect 2006; 134:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/17\">",
"      Ramamurthy T, Garg S, Sharma R, et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 1993; 341:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/18\">",
"      Stoll BJ, Glass RI, Huq MI, et al. Epidemiologic and clinical features of patients infected with Shigella who attended a diarrheal disease hospital in Bangladesh. J Infect Dis 1982; 146:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/19\">",
"      Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008; 56:413.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. First steps for managing an oubreak of acute diarrhea. Geneva, Switzerland: World Health Organization, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/21\">",
"      Victora CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000; 78:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/22\">",
"      Hahn S, Kim S, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children. Cochrane Database Syst Rev 2002; :CD002847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/23\">",
"      Alam NH, Majumder RN, Fuchs GJ. Efficacy and safety of oral rehydration solution with reduced osmolarity in adults with cholera: a randomised double-blind clinical trial. CHOICE study group. Lancet 1999; 354:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/24\">",
"      Gregorio GV, Gonzales ML, Dans LF, Martinez EG. Polymer-based oral rehydration solution for treating acute watery diarrhoea. Cochrane Database Syst Rev 2009; :CD006519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/25\">",
"      Ramakrishna BS, Venkataraman S, Srinivasan P, et al. Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med 2000; 342:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/26\">",
"      Wistr&ouml;m J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med 1992; 117:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/27\">",
"      Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/28\">",
"      Salam I, Katelaris P, Leigh-Smith S, Farthing MJ. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 1994; 344:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/29\">",
"      Mattila L, Peltola H, Siitonen A, et al. Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis 1993; 17:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/30\">",
"      Christopher PR, David KV, John SM, Sankarapandian V. Antibiotic therapy for Shigella dysentery. Cochrane Database Syst Rev 2010; :CD006784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/31\">",
"      Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/32\">",
"      Kariuki S, Hart CA. Global aspects of antimicrobial-resistant enteric bacteria. Curr Opin Infect Dis 2001; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/33\">",
"      Mandomando I, Espasa M, Vall&egrave;s X, et al. Antimicrobial resistance of Vibrio cholerae O1 serotype Ogawa isolated in Manhi&ccedil;a District Hospital, southern Mozambique. J Antimicrob Chemother 2007; 60:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/34\">",
"      Taneja N, Mohan B, Khurana S, Sharma M. Antimicrobial resistance in selected bacterial enteropathogens in north India. Indian J Med Res 2004; 120:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/35\">",
"      Rahman M, Shoma S, Rashid H, et al. Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin. J Health Popul Nutr 2007; 25:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/36\">",
"      Tjaniadi P, Lesmana M, Subekti D, et al. Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. Am J Trop Med Hyg 2003; 68:666.",
"     </a>",
"    </li>",
"    <li>",
"     Surveillance Update. ICDDR,B:Health and Science Bulletin 2010; 8:19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/38\">",
"      Brooks JT, Ochieng JB, Kumar L, et al. Surveillance for bacterial diarrhea and antimicrobial resistance in rural western Kenya, 1997-2003. Clin Infect Dis 2006; 43:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/39\">",
"      Fewtrell L, Kaufmann RB, Kay D, et al. Water, sanitation, and hygiene interventions to reduce diarrhoea in less developed countries: a systematic review and meta-analysis. Lancet Infect Dis 2005; 5:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29976/abstract/40\">",
"      Ejemot RI, Ehiri JE, Meremikwu MM, Critchley JA. Hand washing for preventing diarrhoea. Cochrane Database Syst Rev 2008; :CD004265.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Potential use of oral cholera vaccines. file://www.who.int/topics/cholera/vaccines/use/en/index.html (Accessed on July 13, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13954 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29976=[""].join("\n");
var outline_f29_17_29976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1169885113\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885057\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77501562\">",
"      CLASSIFICATION OF DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885064\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885166\">",
"      Worldwide incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77501856\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885173\">",
"      - Crowding and poor sanitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885180\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885073\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885231\">",
"      Epidemic diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885262\">",
"      Acute watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885269\">",
"      Acute bloody diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77501965\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10153248\">",
"      Complications of acute diarrheal diseases in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H77502176\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885082\">",
"      CLINICAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885090\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885319\">",
"      Rehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77502056\">",
"      - None to moderate hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77502070\">",
"      - Severe hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885312\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77502155\">",
"      - Watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77502169\">",
"      - Dysentery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885338\">",
"      - Antimicrobial resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885345\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885106\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1169885113\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13954|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/39/24191\" title=\"algorithm 1\">",
"      Approach to fluid management in adult with hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13954|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/36/42561\" title=\"picture 1\">",
"      Acute watery diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/53/23390\" title=\"picture 2\">",
"      Entamoeba histolytica trophozoite",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13954|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/11/26812\" title=\"table 1\">",
"      Pathogens causing adult diarrhea developing world",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/28/19916\" title=\"table 2\">",
"      Comparison clinical features epidemic dysentery cholera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/4/27723\" title=\"table 3\">",
"      Potential complications of acute diarrheal disease in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/55/13180\" title=\"table 4\">",
"      Hypovolemia in diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/15/1275\" title=\"table 5\">",
"      Composition hypoosmolar ORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/46/21228\" title=\"table 6\">",
"      Oral antibiotics for suspected cholera",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/10/26795\" title=\"table 7\">",
"      Antimicrobials for the treatment of shigellosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5625?source=related_link\">",
"      Approach to the child with acute diarrhea in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31542?source=related_link\">",
"      Nontyphoidal Salmonella bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39334?source=related_link\">",
"      Treatment and prevention of Shigella infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_17_29977="Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease";
var content_f29_17_29977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29977/contributors\">",
"     Michael J Birrer, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29977/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29977/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/17/29977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin in women exhibit similar clinical characteristics and behavior. As such, these are often combined and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three tumors under the heading EOC.",
"   </p>",
"   <p>",
"    Despite initial therapy, the majority of women will relapse and require retreatment. Taking into account the frequency of each stage of disease and its projected relapse rate, the overall likelihood of relapse after initial therapy for all stages of disease for women with EOC is 62 percent; it is 80 to 85 percent for women who present with abdominal (stage III) or extra-abdominal (eg, liver or lung involvement, stage IV) disease.",
"   </p>",
"   <p>",
"    The management of relapsed disease is stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H760206841#H760206841\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Treatment of recurrent disease'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a PFI of six months or longer are considered to have &ldquo;platinum-sensitive&rdquo; disease. The management of these patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a PFI of less than six months are considered to have &ldquo;platinum-resistant&rdquo; disease. This includes women who experience disease progression during first-line platinum-based therapy, often referred to as having &ldquo;platinum-refractory&rdquo; disease. The management of these patients (collectively referred to as having platinum-resistant EOC) is discussed here.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial diagnosis and management of EOC, the surgical treatment of recurrent EOC and an overview of angiogenesis inhibitors in EOC are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28070?source=see_link\">",
"     \"Surgery for recurrent epithelial ovarian cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11832?source=see_link&amp;anchor=H14635776#H14635776\">",
"     \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Recurrent disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142134507\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of active treatment options available for women with platinum-resistant EOC (ie, relapse less than six months from previous treatment) and the ideal treatment is not known. We prefer sequential single agent treatment rather than combination therapy. For women not previously treated with a taxane as part of a first-line (or adjuvant) treatment, single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is recommended. Multiple studies have demonstrated that paclitaxel is one of the most active agents in EOC, particularly in paclitaxel-na&iuml;ve platinum-resistant EOC in which response rates range between 13 and 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. For women with platinum-resistant EOC after a platinum and taxane combination, our preferred first line agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (PLD) because of its schedule (ie, every four week administration) and lack of typical side effects associated with chemotherapy (eg, little risk of myelosuppression, no risk of alopecia). However, the 2011 drug shortage of PLD has become an issue in the care of patients with recurrent EOC. Other chemotherapy, hormonal, and biologic agents are acceptable alternatives. &nbsp;",
"   </p>",
"   <p>",
"    The role of intraperitoneal (IP) therapy or high dose chemotherapy in the setting of recurrent disease is highly experimental. In one report of IP therapy that included 89 women with persistent or recurrent EOC, 42 percent of women with platinum-sensitive disease had a complete response versus only 7 percent of those with platinum-resistant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/5\">",
"     5",
"    </a>",
"    ]. These response rates are similar to those achieved with intravenous platinum-based therapy in the second-line setting for platinum-resistant EOC and toxicities from IP chemotherapy are greater than IV. Similarly, responses to high dose chemotherapy with autologous hematopoietic cell transplantation are short lived (usually six to nine months) and there is no convincing evidence of a long-term survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250842013#H250842013\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple agents with activity in platinum-resistant epithelial ovarian cancer (EOC) but the ideal agent is not known. A Cochrane systematic review of trials (n=1323) with platinum resistant EOC concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    have similar efficacy, but different patterns of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/9\">",
"     9",
"    </a>",
"    ]. A choice among these agents depends upon the physician&rsquo;s experience, the side effect profile, and prior therapy. In general, we prefer single agent treatment with pegylated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    (PLD) because of its schedule (ie, every four week administration) and lack of typical side effects associated with chemotherapy (eg, little risk of myelosuppression, no risk of alopecia).",
"   </p>",
"   <p>",
"    The following describe prospective studies that have evaluated these agents in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"      <strong>",
"       (PLD)",
"      </strong>",
"      &mdash; In one of the largest randomized studies performed in this population, PLD (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every four weeks) was compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for five days, every three weeks) in 237 women who relapsed after receiving one platinum-containing regimen, of whom 117 were platinum-refractory [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Compared to topotecan, treatment with PLD resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A similar overall response rate (ORR, 20 versus 17 percent)",
"     </li>",
"     <li>",
"      A similar time to progression (TTP, 22 versus 20 weeks)",
"     </li>",
"     <li>",
"      A similar median overall survival (OS, 66 versus 56 weeks)",
"     </li>",
"     <li>",
"      Less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      myelotoxicity, including neutropenia (12 versus 71 percent) and thrombocytopenia (1 versus 35 percent)",
"     </li>",
"     <li>",
"      More episodes of hand-foot syndrome and stomatitis. However, subsequent studies show that this can be minimized by initiating PLD at a lower dose (eg, 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every four weeks), with similar antitumor efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"       \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; Weekly paclitaxel (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for three weeks followed by one week off) showed a 21 percent response rate in a cohort of 48 women with platinum-resistant disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/15\">",
"       15",
"      </a>",
"      ]. Stable disease was seen in 46 percent. The major toxicity was mild neuropathy (grade 2), which occurred in 21 percent. Severe (grade 3) neuropathy was seen in four percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash; Docetaxel (75 to 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      given every 21 days) was evaluated in a cohort of 32 women with an overall response rate (ORR) of 23 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/16\">",
"       16",
"      </a>",
"      ]. Stable disease was achieved by 28 percent. Predominant toxicity was hematologic with serious (grade 4) thrombocytopenia in 50 percent, febrile neutropenia in 33 percent, and grade 4 neutropenia in 72 percent. Non-hematologic toxicities included mild (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      fatigue, nausea, vomiting, and diarrhea.",
"     </li>",
"     <li>",
"      <strong>",
"       Nanoparticle albumin-bound (nAb)",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      &mdash; NAb-paclitaxel (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      given weekly for three weeks",
"      <span class=\"nowrap\">",
"       on/one",
"      </span>",
"      week off) was administered to 51 women in a Gynecologic Oncology Group (GOG) study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/17\">",
"       17",
"      </a>",
"      ]. The ORR was 23 percent with stable disease in 36 percent. Moderate (grade 3) neutropenia was seen in 12 percent of women with mild-moderate neuropathy (grade",
"      <span class=\"nowrap\">",
"       2/3).",
"      </span>",
"      Otherwise, there was no significant toxicity. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      &mdash; Oral etoposide (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for 21 days every four weeks) was given to 41 women with an ORR of 27 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/18\">",
"       18",
"      </a>",
"      ]. Serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity consisted of neutropenia (45 percent) and leukopenia (41 percent). There were two deaths in this trial from neutropenic sepsis and thrombocytopenic bleeding.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       Topotecan",
"      </a>",
"      &mdash; The North Eastern German Society of Gynecologic Oncology conducted a randomized trial of 194 women with platinum-resistant disease who received either daily times five treatment (1.25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      on days 1 through 5 of a 21 day cycle) or weekly topotecan (4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      days 1, 8, and 15 of a 28 day cycle) or [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/19\">",
"       19",
"      </a>",
"      ]. Compared to weekly dosing, the daily times five regimen produced:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significantly higher ORR (19 versus 9 percent)",
"     </li>",
"     <li>",
"      Similar rate of stable disease (approximately 40 percent in both groups)",
"     </li>",
"     <li>",
"      No difference in median progression free survival (PFS, 3 versus 4 months) or median OS (9 months in each)",
"     </li>",
"     <li>",
"      No difference in quality of life was seen between the treatment groups",
"     </li>",
"     <li>",
"      However, weekly dosing was associated with a 62 percent relative risk reduction in the occurrence of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      &mdash; Gemcitabine (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8 of a 21-day cycle) was directly compared to PLD (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day one of a 28-day cycle) in a randomized trial of 195 women with platinum-resistant EOC [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/20\">",
"       20",
"      </a>",
"      ]. Compared to PLD, treatment with gemcitabine resulted in:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A similar ORR (9 versus 11 percent)",
"     </li>",
"     <li>",
"      A higher proportion of stable disease (55 versus 39 percent)",
"     </li>",
"     <li>",
"      Similar median PFS (4 versus 3 months)",
"     </li>",
"     <li>",
"      Similar median overall survival (13 versus 14 months)",
"     </li>",
"     <li>",
"      Toxicity associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      included severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      fatigue (11 percent),",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      (13 percent), and neutropenia (38 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      &mdash; Vinorelbine (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8 of a 21-day cycle) was given to 33 women in a large phase II study and showed an ORR of 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/21\">",
"       21",
"      </a>",
"      ]. However, these results were not confirmed in a study of 81 women conducted by the Southwest Oncology Group (SWOG) where the ORR was only 3 percent, and the median survival duration 10 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/22\">",
"       22",
"      </a>",
"      ]. Serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicity was limited to neutropenia (28 percent) and abdominal pain (5 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      &mdash; Ifosfamide (1.0 or 1.2",
"      <span class=\"nowrap\">",
"       gm/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for five days every four weeks) was given to 41 women with platinum-refractory disease with an ORR of 12 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/23\">",
"       23",
"      </a>",
"      ]. Toxicity was substantial with severe neutropenia in 20 percent, thrombocytopenia in 14 percent, and central nervous toxicity (eg, hallucinations and disorientation) in 12 percent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       Pemetrexed",
"      </a>",
"      &mdash; Pemetrexed (900",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 21 days) was given to 51 patients on a GOG study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/24\">",
"       24",
"      </a>",
"      ]. The ORR was 21 percent with an additional 35 percent experiencing stable disease. Serious toxicities (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      included neutropenia (42 percent) and constitutional deterioration (15 percent). A European study randomized 102 women to treatment using the standard dose used above or a lower dose (500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 21 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/25\">",
"       25",
"      </a>",
"      ]. The ORR with either dose was lower than that seen in the GOG experience (9 and 10 percent for the standard and lower doses, respectively). The lower dose resulted in fewer side effects (17 versus 28 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that there are a number of options available, the order of agents should be individualized based upon patient preference. Often the better choice is to offer a patient a well-designed, scientifically valid, peer-reviewed clinical trial. In the United States, additional information and instructions for referring a patient to an appropriate research center can be obtained at the National Institutes of Health",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     clinical trials website",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142136994\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there are a number of active treatment options available for women with platinum-resistant EOC (ie, relapse less than six months from previous treatment), we prefer sequential single agent treatment rather than combination therapy. Combination therapy is not recommended in this population for reasons due to the additive toxicity risks and no evidence that it improves survival outcomes. This is illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      versus a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      combination",
"      <strong>",
"      </strong>",
"      &mdash; A phase III trial by the Group d&rsquo;Investigateurs Nationaux pour l&rsquo;Etude des Cancers Ovariens (GINECO) group enrolled 165 women with platinum-resistant cancer and randomly assigned treatment using weekly paclitaxel (80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /week)",
"      </span>",
"      alone, in combination with carboplatin (area under the curve [AUC] 5), or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /week)",
"      </span>",
"      on a 28-day cycle, with the following results [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/26\">",
"       26",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A higher rate of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia (13, 54, and 42 percent, with single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , paclitaxel plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , or paclitaxel plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      , respectively)",
"     </li>",
"     <li>",
"      A higher incidence of febrile neutropenia (0, 4, and 5 percent, respectively)",
"     </li>",
"     <li>",
"      No difference in ORR (37, 39 and 35 percent, respectively)",
"     </li>",
"     <li>",
"      No difference in PFS among the treatment arms (hazard ratio for recurrence [HR] 0.92, 95 percent CI, 0.77-1.11) or between single agent and combination chemotherapy (HR for recurrence 0.95, 95% CI 0.69-1.32)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      &mdash; The combination of cisplatin (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) and gemcitabine (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8) was administered on 28-day cycles to 57 women in a GOG phase II study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/27\">",
"       27",
"      </a>",
"      ]. The overall response rate was 16 percent with stable disease achieved in 54 percent. The median TTP was five months. Toxicity (grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      adverse events) was substantial with this regimen; neutropenia occurred in 67 percent and gastrointestinal toxicity occurred in 12 percent. The low response rate, short progression free survival, and significant toxicity argue against its routine use in this population.",
"     </li>",
"     <li>",
"      Alternating doublets &mdash; In a phase II study, 45 patients were treated with three",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      -containing doublets administered sequentially every three weeks for a total of nine cycles [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/28\">",
"       28",
"      </a>",
"      ]. The chemotherapy administered each cycle consisted of one of three doublets, in the following order: carboplatin (AUC 5) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8); carboplatin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (PLD, 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       );",
"      </span>",
"      carboplatin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ).",
"      </span>",
"      The ORR was 39 percent with median PFS and OS of 7 and 19 months, respectively. The rates of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      neutropenia and thrombocytopenia were 40 and 20 percent, respectively. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142135454\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with radiologic evidence of disease progression but with little or no symptoms associated with recurrent EOC, endocrine therapy can be a reasonable option. These studies illustrate the potential role for endocrine agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      - The efficacy of tamoxifen was explored in a Cochrane review that included 623 women with recurrent EOC who participated in one of 14 studies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/29\">",
"       29",
"      </a>",
"      ]. Overall, 60 women (10 percent) achieved an objective response to tamoxifen alone, although the range within individual studies was 0 to 56 percent. An additional 32 percent achieved stable disease for periods of longer than four weeks.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       Letrozole",
"      </a>",
"      - In a phase II trial of letrozole in 42 women with estrogen receptor positive recurrent EOC based on CA-125 values, a serologic decrease in CA-125 &gt;50 percent was seen in 17 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/30\">",
"       30",
"      </a>",
"      ]. Radiologic response was noted in three of 33 women (9 percent).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"       Fulvestrant",
"      </a>",
"      - In a phase II trial of the selective estrogen receptor down-regulator, fulvestrant (500 mg IM on day 1 then 250 mg on days 15, 29, and then every 28 days) was administered to 26 women with estrogen-receptor positive recurrent EOC [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/31\">",
"       31",
"      </a>",
"      ]. While there were no objective responses, 50 percent had stable disease and one patient normalized a previously elevated serum CA-125. The median time to disease progression was 60 days, and treatment was well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4964?source=see_link\">",
"     fulvestrant",
"    </a>",
"    selected patients with ER-positive disease, we do not routinely perform ER-testing in women with recurrent EOC. We reserve the use of endocrine therapy to women with asymptomatic recurrent disease. In addition, we prefer observation to endocrine therapy in the setting of CA-125 relapse given the results of a randomized trial showing no benefit to initiation of treatment solely defined by CA-125. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142138325\">",
"    <span class=\"h2\">",
"     Biologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic therapy has been a major emphasis of research in EOC with efforts focused on targeting vascular endothelial growth factor (VEGF), its receptor (VEGFR), and angiogenesis pathways. Among the agents being developed in platinum-resistant ovarian cancer,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    has been the most extensively studied [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The preliminary results of a phase III trial suggest that chemotherapy plus bevacizumab is a reasonable combination option in this population.",
"   </p>",
"   <p>",
"    In the AURELIA study, 361 patients with platinum-resistant ovarian cancer (defined as progression &le;6 months after &ge;4 platinum-based cycles) were randomly assigned to chemotherapy with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/34\">",
"     34",
"    </a>",
"    ]. Chemotherapy options were based on the investigator&rsquo;s choice of one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 15, and 22 every four weeks (n=115)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       Topotecan",
"      </a>",
"      4",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, and 15 every four weeks (or 1.25",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 through 5 every three weeks) (n=120)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       Pegylated liposomal doxorubicin",
"      </a>",
"      (PLD) 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1 every four weeks (n=126)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With a median follow-up of 13.5 months, compared to chemotherapy alone, chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A statistically significant improvement in the ORR (31 versus 13 percent, respectively).",
"     </li>",
"     <li>",
"      A reduction in the risk of disease progression (HR 0.48, 95% CI 0.38-0.60; median duration 7 versus 3 months).",
"     </li>",
"     <li>",
"      An increase in the rate of grade 2 or greater adverse events, including hypertension (20 versus 7 percent) and proteinuria (0.6 versus 11 percent). Four patients (2.2 percent) experienced a GI perforation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subset analysis of the AURELIA study that evaluated the outcomes associated with the individual regimens was presented at the 2012 European Society of Medical Oncology (ESMO) meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/35\">",
"     35",
"    </a>",
"    ]. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to chemotherapy consistently resulted in better outcomes compared to treatment with chemotherapy alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , the ORR was 52 versus 29 percent with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , respectively; median PFS was 10 versus 4 months (HR 0.46, 95% CI 0.30-0.71).",
"     </li>",
"     <li>",
"      Among those who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      , the ORR was 23 versus 3 percent; median PFS was 6 versus 2 months (HR 0.32, 95% CI 0.21-0.49).",
"     </li>",
"     <li>",
"      Among those who received PLD, the ORR was 18 versus 8 percent; median PFS was 5 versus 4 months (HR 0.57, 95% 0.39-0.83). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support the use of chemotherapy plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in the treatment of women with platinum-resistant ovarian cancer. We await further follow-up to determine the impact of bevacizumab treatment on overall survival. A more extensive discussion of angiogenesis inhibitors in the treatment of EOC is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11832?source=see_link\">",
"     \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142679\">",
"    <span class=\"h2\">",
"     Prolonging the platinum free interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with platinum-resistant EOC, we do not retreat with platinum, although some experts would consider platinum re-treatment in select patients. Whether women with platinum-resistant EOC can become &ldquo;re-sensitized&rdquo; to platinum treatment by artificially prolonging the platinum-free interval by treatment with non platinum agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ) prior to platinum re-treatment is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As an example, in one study, 30 patients with platinum-resistant EOC who went on to receive platinum re-treatment after intervening non-platinum based therapy were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/37\">",
"     37",
"    </a>",
"    ]. The overall response rate was 23 percent. Multivariate analysis suggested that patients who did not respond to prior platinum-based treatment or who had received more than three intervening lines of treatment were not likely to benefit from this strategy. Unfortunately, there are no randomized trials that directly test this hypothesis, and the available data are insufficient to support the use of such a strategy until randomized trials determine its merit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284577919\">",
"    <span class=\"h1\">",
"     IMPACT OF LATER-LINE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who relapse after first-line or subsequent treatment and desire further therapy, continuing therapy appears to be beneficial. In an analysis of 1620 patients who had originally participated in a first-line clinical trial, subsequent treatment for recurrent disease resulted in a significant improvement in median OS in the second-line (14 versus 4 months, HR 0.38, 95% CI 0.32-0.46), third-line (11 versus 3 months, HR 0.35, 95% CI 0.28-0.45), and fourth-line setting (8 versus 3 months, HR 0.53, 95% CI 0.37-0.74) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142138523\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142376\">",
"    <span class=\"h2\">",
"     Recurrence based on CA-125 only",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ovarian cancer may be followed serially with the serum tumor marker, CA-125. In some cases, patients with an elevated CA-125 may be defined as having disease progression (sometimes referred to as serologic progression), even in the absence of clinical symptoms or radiologic findings. For patients who experience a rising CA-125 within six months of completion of prior treatment, we recommend surveillance rather than chemotherapy because a randomized trial showed no survival benefit to early compared to delayed treatment (ie, treatment initiated based on objective evidence of disease progression). This trial is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the administration of endocrine therapy in patients with relapse by CA-125 alone because they appear to have some activity and are less toxic than chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link&amp;anchor=H23567221#H23567221\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\", section on 'Recurrence based on CA-125 only'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142138770\">",
"    <span class=\"h2\">",
"     Malignant bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most common problems faced by women with recurrent advanced EOC is bowel obstruction, which for the majority of women heralds a terminal event [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Options for treatment must focus on comfort and palliation (eg, placement of a percutaneous endoscopic gastrotomy tube to prevent vomiting), as both chemotherapy and surgical options have very limited utility. While some clinicians offer chemotherapy in hopes of bowel recovery, the limited data available suggest chemotherapy is not an effective treatment to restore bowel function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/41\">",
"     41",
"    </a>",
"    ]. For women who develop a malignant bowel obstruction, careful consideration of treatment (chemotherapy or surgery) should take into account the individual patient&rsquo;s clinical situation, performance status, preferences of treatment, and overall prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28070?source=see_link\">",
"     \"Surgery for recurrent epithelial ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3034406\">",
"    <span class=\"h2\">",
"     Recurrent ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large proportion of women with platinum-resistant EOC develop ascites, which is frequently resistant to systemic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/42\">",
"     42",
"    </a>",
"    ]. Therapeutic paracentesis provides relief, although it is usually temporary with repeat abdominal paracentesis needed frequently to control symptoms (distention or shortness of breath). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=see_link\">",
"     \"Malignancy-related ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the evidence is limited, angiogenesis inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , catumaxomab,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    ) have been used to manage refractory ascites and provide symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-five women with refractory EOC-related ascites were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two weeks) or placebo for at least 60 days [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/46\">",
"       46",
"      </a>",
"      ]. Compared to placebo, patients who received aflibercept had a significantly longer median time to repeat paracentesis (55 versus 23 days), although they also experienced more toxicity including dyspnea (20 versus 8 percent) and gastrointestinal perforation (10 versus 0 percent).",
"     </li>",
"     <li>",
"      In a single institution report, four women with end-stage EOC and symptomatic ascites received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks) in an attempt to palliate symptoms and reduce need for repeat paracentesis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/43\">",
"       43",
"      </a>",
"      ]. All patients reported subjective relief with none requiring repeat paracentesis after treatment was started (range in duration of treatment was 12 to 24 weeks). None experienced a gastrointestinal perforation but two patients developed mild to moderate (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women with platinum-resistant end-stage EOC who develop recurrent ascites, chemotherapy may be of limited use. We suggest management with paracentesis for symptomatic relief. The use of angiogenesis inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is reasonable, particularly for women requiring frequent paracentesis for control of ascites. The risk of toxicity, including gastrointestinal perforation, should be considered on an individual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142492\">",
"    <span class=\"h2\">",
"     Genome wide tumor analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individualized molecular tumor profiling holds the promise of enabling personalized selection of molecularly targeted treatment based on the specific genotype identified. Several platforms are available including the Caris Target Now&trade; and SNaPshot&trade; technology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29977/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, these assays require further evaluation to determine the appropriate use of genome wide analysis in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142499\">",
"    <span class=\"h2\">",
"     In vitro chemosensitivity and resistance assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro assays that aim to help select the optimal chemotherapy regimen (sensitivity assays) or identify those agents least likely to be effective (resistance assays) have been developed. These assays are covered separately but for women with platinum-resistant disease, we agree with guidelines from the American Society of Clinical Oncology and do not recommend their use in selection of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H250841395#H250841395\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'In vitro chemosensitivity and resistance assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142309\">",
"    <span class=\"h2\">",
"     Heated intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of heated IP chemotherapy (HIPEC) is indicated for mucinous carcinomas, such as appendiceal carcinoma and pseudomyxoma peritonei. Given the tendency of recurrent ovarian cancer to present as abdominal disease, there is growing interest in the use of heated IP chemotherapy (HIPEC) for women with recurrent EOC following surgical cytoreduction. However, we consider HIPEC an investigational modality for the treatment of patients with platinum-recurrent EOC. The potential role of HIPEC as a treatment option in recurrent EOC is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link&amp;anchor=H16216188#H16216188\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\", section on 'Heated intraperitoneal chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"       \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who experience a recurrence, the selection of therapy is commonly based upon whether women are \"sensitive\" or \"resistant\" to platinum-based treatment. Patients who respond to initial platinum-based therapy and have a significant relapse-free interval (more than six months) have a high probability of responding again to platinum-based treatment at the time of relapse. These patients are termed \"platinum-sensitive\". Women who progress on or relapse within six months of completion of prior platinum-based therapy are considered &ldquo;platinum-resistant&rdquo;. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H760206841#H760206841\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Treatment of recurrent disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Given the incurable nature of recurrent EOC, we recommend delay of treatment for women who relapse solely by CA-125. We reserve chemotherapy or other treatments for women who develop or are about to develop signs or symptoms related to recurrent EOC. For women with asymptomatic disease, endocrine therapy is a reasonable option. (See",
"      <a class=\"local\" href=\"#H1142135454\">",
"       'Endocrine therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H32#H32\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with recurrent platinum-resistant EOC, we recommend sequential single agent chemotherapy rather than combination chemotherapy due to increased toxicity and lack of convincing increased benefit (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      because of its every four week cycle length and lack of significant side effects (eg, hair loss, myelosuppression). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Single agent therapy'",
"      </a>",
"      above.) However, the 2011 drug shortage of PLD has become an issue in the care of patients with recurrent EOC.",
"     </li>",
"     <li>",
"      We do not retreat with platinum following intervening non-platinum treatment because there are few data to support this strategy. However, some clinicians would consider platinum retreatment in select patients. (See",
"      <a class=\"local\" href=\"#H1142679\">",
"       'Prolonging the platinum free interval'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who develop a malignant bowel obstruction, options for treatment must focus on comfort and palliation, as both chemotherapy and surgical options have very limited utility. An individualized approach to the use of chemotherapy in this situation should take into account the individual patient&rsquo;s clinical situation, performance status, preferences of treatment, and overall prognosis. (See",
"      <a class=\"local\" href=\"#H1142138770\">",
"       'Malignant bowel obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with platinum-resistant end-stage EOC who develop recurrent ascites, chemotherapy may be of limited use. Patients are candidates for paracentesis for symptomatic relief. Alternatively, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      is also reasonable, but the risk of toxicity, including gastrointestinal perforation, should be considered on an individual basis. (See",
"      <a class=\"local\" href=\"#H3034406\">",
"       'Recurrent ascites'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/1\">",
"      Seewaldt VL, Greer BE, Cain JM, et al. Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 1994; 170:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/2\">",
"      Gore ME, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/3\">",
"      Bruzzone M, Catsafados E, Miglietta L, et al. Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients. Oncology 1996; 53:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/4\">",
"      Ezcurdia L, Jovtis SL, Mickiewicz E, et al. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group. Semin Oncol 1997; 24:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/5\">",
"      Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/6\">",
"      Herrin VE, Thigpen JT. High-dose chemotherapy in ovarian carcinoma. Semin Oncol 1999; 26:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/7\">",
"      Stiff PJ, Veum-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000; 133:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/8\">",
"      Sarosy GA, Reed E. Autologous stem-cell transplantation in ovarian cancer: is more better? Ann Intern Med 2000; 133:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/9\">",
"      Peng LH, Chen XY, Wu TX. Topotecan for ovarian cancer. Cochrane Database Syst Rev 2008; :CD005589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/10\">",
"      Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/11\">",
"      Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/12\">",
"      Lorusso D, Naldini A, Testa A, et al. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 2004; 67:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/13\">",
"      Rose PG, Maxson JH, Fusco N, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 2001; 82:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/14\">",
"      Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/15\">",
"      Gynecologic Oncology Group, Markman M, Blessing J, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/16\">",
"      Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant M&uuml;llerian carcinoma. J Clin Oncol 2000; 18:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/17\">",
"      Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/18\">",
"      Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/19\">",
"      Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011; 29:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/20\">",
"      Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/21\">",
"      S&oslash;rensen P, H&oslash;yer M, Jakobsen A, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol 2001; 81:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/22\">",
"      Rothenberg ML, Liu PY, Wilczynski S, et al. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 2004; 95:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/23\">",
"      Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/24\">",
"      Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009; 27:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/25\">",
"      Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009; 45:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/26\">",
"      Lortholary A, Largillier R, Weber B, et al. Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 2012; 23:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/27\">",
"      Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 103:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/28\">",
"      Pectasides D, Pectasides E, Papaxoinis G, et al. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma. Gynecol Oncol 2010; 118:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/29\">",
"      Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev 2001; :CD001034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/30\">",
"      Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 2007; 13:3617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/31\">",
"      Argenta PA, Thomas SG, Judson PL, et al. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol 2009; 113:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/32\">",
"      Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/33\">",
"      McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011; 117:3731.",
"     </a>",
"    </li>",
"    <li>",
"     Pujade-Lauraine E, Hilpert F, Weber B,  et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 30, 2012 (suppl; abstr LBA5002^). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=94636 (Accessed on June 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/35\">",
"      Poveda AM, Selle F, Hilpert F, et al. Weekly paclitaxel, pegylated liposomal doxorubicin or topotecan &plusmn; bevacizumab in platinum-resistant ovarian cancer: analysis by chemotherapy cohort in the GCIG AURELIA randomised phase III trial. Ann Oncol 2012; 23:ixe17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/36\">",
"      Tanguay JS, Ansari J, Buckley L, Fernando I. Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer 2009; 19:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/37\">",
"      Leitao MM Jr, Hummer A, Dizon DS, et al. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 2003; 91:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/38\">",
"      Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012; 23:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/39\">",
"      Tamussino KF, Lim PC, Webb MJ, et al. Gastrointestinal surgery in patients with ovarian cancer. Gynecol Oncol 2001; 80:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/40\">",
"      Clarke-Pearson DL, Chin NO, DeLong ER, et al. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol 1987; 26:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/41\">",
"      Abu-Rustum NR, Barakat RR, Venkatraman E, Spriggs D. Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. Gynecol Oncol 1997; 64:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/42\">",
"      Kobold S, Hegewisch-Becker S, Oechsle K, et al. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009; 14:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/43\">",
"      Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006; 102:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/44\">",
"      Hamilton CA, Maxwell GL, Chernofsky MR, et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008; 111:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/45\">",
"      Str&ouml;hlein MA, Heiss MM. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol 2010; 6:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/46\">",
"      Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012; 13:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/47\">",
"      Bellati F, Napoletano C, Ruscito I, et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 2010; 28:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29977/abstract/48\">",
"      Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877.",
"     </a>",
"    </li>",
"    <li>",
"     Sales E, Penson RT, Sullivan LA, et al. A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. J Clin Oncol 30, 2012 (suppl; abstr 5029).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3240 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29977=[""].join("\n");
var outline_f29_17_29977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1142134507\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142136994\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142135454\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142138325\">",
"      Biologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142679\">",
"      Prolonging the platinum free interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284577919\">",
"      IMPACT OF LATER-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1142138523\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142376\">",
"      Recurrence based on CA-125 only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142138770\">",
"      Malignant bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3034406\">",
"      Recurrent ascites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142492\">",
"      Genome wide tumor analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142499\">",
"      In vitro chemosensitivity and resistance assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1142309\">",
"      Heated intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39928?source=related_link\">",
"      Malignancy-related ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=related_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28070?source=related_link\">",
"      Surgery for recurrent epithelial ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/35/11832?source=related_link\">",
"      The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_17_29978="Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera";
var content_f29_17_29978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29978/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29978/contributors\">",
"     Josef T Prchal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29978/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/17/29978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/17/29978/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/17/29978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute polycythemia refers to settings in which there is an increase in red cell mass. This condition has also been called erythrocytosis, with three forms being recognized (",
"    <a class=\"graphic graphic_table graphicRef76036 \" href=\"UTD.htm?30/46/31468\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary polycythemia",
"      </strong>",
"      &mdash; Primary polycythemia is caused by acquired (somatic) or inherited (germline) mutations expressed within the erythroid progenitors that increase their proliferation; this can occur in polycythemia vera or the rare polycythemias such as those due to \"gain-of-function\" of the erythropoietin receptor (EPOR). The result of these mutations is an increased accumulation of erythrocytes (ie, polycythemia).",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary polycythemia",
"      </strong>",
"      &mdash; Secondary polycythemia refers to conditions in which there are circulating plasma factors stimulating erythropoiesis, usually erythropoietin (EPO) or an anabolic steroid (eg, testosterone). In rare instances, exposure to cobalt, dysregulated",
"      <span class=\"nowrap\">",
"       angiotensin/angiotensin",
"      </span>",
"      receptor 1 erythroid signaling, such as that seen in postrenal transplant erythrocytosis, and elevated plasma levels of insulin-like growth factor-1 have also been shown to stimulate erythropoiesis. Some secondary polycythemias are acquired, most often from EPO stimulation by hypoxia; they can also result from an EPO-secreting tumor. Secondary polycythemias can also be congenital, such as those arising from mutant hemoglobins associated with increased oxygen affinity or an inherited defect of 2,3 BPG (2,3 DPG) synthesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link&amp;anchor=H21#H21\">",
"       \"Diagnostic approach to the patient with polycythemia\", section on 'Evaluation of secondary erythrocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Congenital disorders of hypoxia sensing",
"      </strong>",
"      &mdash; Some of these disorders share features of both primary (increased sensitivity of erythroid progenitors to EPO) and secondary polycythemia (elevated EPO levels). This was demonstrated in Chuvash polycythemia and in some patients with gain-of-function HIF-2 alpha gene mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Congenital polycythemias with established molecular lesions due to germline mutations that either modify hemoglobin oxygen affinity or modify the normal response to hypoxia will be discussed here. Current understanding of the molecular pathogenesis of polycythemia vera will also be discussed here. The clinical approaches to the patient with polycythemia or suspected polycythemia vera are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link\">",
"     \"Diagnostic approach to the patient with polycythemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REGULATION OF ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoiesis is the physiologic process involved in the production and renewal of the red blood cell mass. A detailed discussion of the regulation of this process is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .) It is useful, however, to briefly review its basic aspects in order to appreciate the potential mechanisms by which polycythemia can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal hormone that regulates erythropoiesis is EPO which, in adults, in primarily secreted by the kidney. Variable levels of EPO are required at the different stages of erythroid maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/1\">",
"     1",
"    </a>",
"    ]. It is most important for terminal maturation of erythroid cells at the level of the CFU-E (colony-forming units erythroid) during adult erythropoiesis. Thus, mice with homozygous null mutations of the EPO or EPO receptor (EPOR) genes form early erythroid progenitors that fail to differentiate into mature erythrocytes and die [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, the pluripotent stem cells and primitive progenitors (ie, early BFU-E), require stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interleukin (IL)-3 for growth in addition to EPO (",
"    <a class=\"graphic graphic_figure graphicRef70092 \" href=\"UTD.htm?12/31/12799\">",
"     figure 1",
"    </a>",
"    ). However, early erythroid progenitors (BFU-E) also express EPO, which may contribute to the local regulation of erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oxygen sensor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major stimulus for EPO production is decreased oxygen delivery due to reduced red blood cell mass (anemia) or decreased O2 saturation of red cell hemoglobin (hypoxemia). This indispensable physiological regulatory mechanism for the body's response to hypoxia has been clarified, as described in the following paragraphs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H19#H19\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia-inducible factor and the response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypoxic stimulation of the oxygen sensor-signaling pathway results in increased production of hypoxia inducible factors (HIF-1 and HIF-2). HIF-2 is the major enhancer for EPO gene transcriptional activation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/7\">",
"     7",
"    </a>",
"    ]. HIF-1 and HIF-2 alpha subunits&rsquo; protein levels are induced by hypoxia and decay rapidly in normoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIF-1 and HIF-2 are essential for life; they play an important role in cellular adaptation to hypoxia by controlling transcription of not only the EPO gene but also many other genes not only essential for erythropoiesis but also for other tissues and functions, including vascular endothelial growth factor (VEGF) and its receptor, energy metabolism (ie, the glucose transporter and glycolytic enzymes), iron metabolism (ie, hepcidin and transferrin receptor), and cellular development. HIFs also play a major role in cancer and facilitate the unique energy metabolism of cancer cells, known as the Warburg effect. Mice lacking the HIF-1 alpha and HIF-2 genes die at midgestation, while heterozygotes, although developmentally normal and similar to normal mice under normoxic conditions, fail to respond adequately to chronic hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/9\">",
"     9",
"    </a>",
"    ]. Selective blocking of HIF-1 in mice by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIF-alpha subunits (there are three isoforms: HIF-1 alpha, HIF-2 alpha, and HIF-3 alpha) are rapidly destroyed in the presence of oxygen by a mechanism that involves ubiquitylation by the von Hippel-Lindau tumor suppressor (pVHL) E3 ligase complex. This process is suppressed by hypoxia and iron chelation and regulated by a proline hydroxylase enzyme. This complex constitutes a cellular oxygen sensor (",
"    <a class=\"graphic graphic_figure graphicRef53801 \" href=\"UTD.htm?3/26/3503\">",
"     figure 2",
"    </a>",
"    ) and mutations along this pathway have been associated with various polycythemic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/4,5,11\">",
"     4,5,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'von Hippel Lindau gene mutation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is likely that the HIF complex is also involved in the adaptation of cancer cells to hypoxic tumor microenvironments [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Erythropoietin receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of EPO on progenitor cells is mediated by a specific receptor (EPOR) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/13\">",
"     13",
"    </a>",
"    ]. The interaction of EPO with its receptor leads to conformational chances of EPOR homodimers and signal transduction that results in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stimulation of mitogenicity (proliferation) of erythroid progenitor cells",
"     </li>",
"     <li>",
"      Differentiation by induction of erythroid-specific expression of proteins",
"     </li>",
"     <li>",
"      Prevention of apoptosis of erythroid progenitors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cytoplasmic portion of the EPOR distal to the transmembrane domain is a",
"    <strong>",
"     positive",
"    </strong>",
"    regulatory domain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/15\">",
"     15",
"    </a>",
"    ] that interacts with Janus 2 tyrosine kinase (JAK2). Immediately after EPO binding, JAK2 phosphorylates itself, the EPOR, and the STAT5 transcription factor, initiating a cascade of erythroid-specific signaling and prevention of apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, even more distal, the C-terminal cytoplasmic portion of the EPOR functions as a",
"    <strong>",
"     negative",
"    </strong>",
"    regulatory domain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/15\">",
"     15",
"    </a>",
"    ]. Hematopoietic cell phosphatase (HCP, also called SH protein tyrosine phosphatase, SHP-1, and SH-PTP1) interacts with this portion of the EPOR and downregulates signal transduction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/17\">",
"     17",
"    </a>",
"    ]. Mutants lacking this portion of the EPOR are hypersensitive to EPO and display prolonged EPO-induced autophosphorylation of JAK2 and increased proliferation of erythroid progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the discovery of EPO and its receptor, a mutation or other abnormality of the EPOR has seemed a logical explanation for various hematological disorders characterized by dysregulation of erythropoiesis. Thus far, gain-of-function EPOR mutations have only been demonstrated in a small number of patients with primary familial and congenital polycythemia (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. All EPOR gene mutations associated with this disorder lead to a truncated receptor that lacks the C-terminal negative regulatory domain of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Insulin-like growth factor-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the in vitro studies that provided information about the hierarchy of regulation of erythropoiesis were performed in the presence of serum and serum-component proteins that might stimulate or inhibit erythropoiesis. One such stimulator is insulin-like growth factor-I (IGF-1), which has EPO-like activity that targets circulating early erythroid progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IGF-I may also be important in patients with end-stage renal disease. Some of these patients have normal hematocrit that cannot be correlated with serum EPO concentrations. Serum IGF-I is increased in such patients and the serum stimulates marrow CFU-E growth via an effect that is partially blocked by anti-IGF-I antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/24\">",
"     24",
"    </a>",
"    ]. Similar observations have been made in patients with post-renal transplant erythrocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for a role of angiotensin II in the regulation of erythropoiesis comes mainly from the well described therapeutic effect of angiotensin converting enzyme (ACE) inhibitors and the specific angiotensin II type 1 (AT1) receptor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    on erythrocytosis following renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In addition, ACE inhibitors can induce a mild, reversible anemia in some renal transplant recipients without erythrocytosis and can increase EPO requirements in some patients on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AT1 has been identified on erythroid progenitors, suggesting that angiotensin II may play a direct role in the regulation of erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/29\">",
"     29",
"    </a>",
"    ]. The observation that angiotensin II intracellular transduction includes JAK2 kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/30\">",
"     30",
"    </a>",
"    ], an enzyme that, as described above, plays an important role in EPO signaling, suggests the possibility of a shared signal transduction pathway between EPO and angiotensin II. It is therefore possible that some of the as yet uncharacterized genotypes of familial and congenital polycythemias could be due to alterations in angiotensin",
"    <span class=\"nowrap\">",
"     II/",
"    </span>",
"    AT1 receptor signaling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONGENITAL POLYCYTHEMIAS WITH AUGMENTED HYPOXIA SENSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxia sensing is central to the regulation of many physiological functions and to many known and yet to be elucidated gene transcriptions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/6,31\">",
"     6,31",
"    </a>",
"    ]. The following disorders with defined mutations in hypoxia-sensing pathways (HIF dysregulation) were identified because of the presence of an elevated hematocrit. These include Chuvash polycythemia, proline hydroxylase 2 (PHD2) (loss-of-function) mutations, and HIF-2 alpha (gain-of-function) mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/21\">",
"     21",
"    </a>",
"    ]. Clearly, while the elevated EPO (or inappropriately normal EPO levels for their elevated red cell mass) played a role in their identification, there is a growing list of other functional dysregulation associated with augmented HIF activity in normoxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chuvash Polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary and secondary congenital polycythemias occur sporadically, without a seeming predilection for a particular population. In contrast, Chuvash polycythemia is a form of congenital polycythemia that is endemic in the Chuvash population of the Russian Federation (mid-Volga region of European Russia). There are more than 103 cases from 81 families that were studied in the published literature with an autosomal recessive pattern of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. This mutation has now been reported worldwide, albeit occurring sporadically [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], and in most instances presents on the same haplotype, indicating an origin from the same founder [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/37\">",
"     37",
"    </a>",
"    ]. Another endemic locus of Chuvash polycythemia has been reported in the Southern Italian island of Ischia, with a gene frequency even higher than that in the Chuvash Autonomous Republic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chuvash polycythemia causes thrombotic and hemorrhagic vascular complications that lead to early mortality, usually before the age of 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/39\">",
"     39",
"    </a>",
"    ]. The serum EPO concentration in polycythemic patients is elevated or inappropriately normal for the given elevation of the hematocrit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] and serum hepcidin levels are reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/41\">",
"     41",
"    </a>",
"    ], consistent with results showing that the HIF pathway is engaged in coordinate regulation of iron metabolism and erythropoiesis through upregulation of EPO and downregulation of hepcidin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/42\">",
"     42",
"    </a>",
"    ]. However, erythrocyte progenitors are hypersensitive to EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/40\">",
"     40",
"    </a>",
"    ], a finding that blurs the distinction between primary and secondary polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     von Hippel Lindau gene mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A causative mechanism in Chuvash polycythemia (CP) established it as the first recognized congenital abnormality in the oxygen-sensing pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/43\">",
"     43",
"    </a>",
"    ], due to a constitutive up-regulation of HIF1-alpha in this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H18#H18\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia and EPO expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CP gene was localized by positional cloning to a mutation of the von Hippel-Lindau (VHL) gene found in both alleles of all CP patients and in one allele of all CP carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/40\">",
"     40",
"    </a>",
"    ]. This is a somewhat surprising finding, since the tumors that occur by somatic mutation in &ldquo;",
"    <em>",
"     VHL",
"    </em>",
"    tumor predisposition syndrome&rdquo;, (ie, pheochromocytoma, renal cell carcinoma, and hemangioblastomas) are not seen in patients with CP or their heterozygous relatives, although, on the other hand, the latter tumors can be associated with polycythemia. This has been attributed, at least in part, to the degree of the mutation&rsquo;s interference with the inhibition of the hypoxia signaling pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=see_link\">",
"     \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to the patient with polycythemia\", section on 'Tumor polycythemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that the mutations that cause a &ldquo;weak&rdquo; deficiency in HIF alpha regulation do not promote tumorigenesis, whereas those that &ldquo;have more deleterious effects&rdquo; are characterized by the development of multiple tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/44\">",
"     44",
"    </a>",
"    ]. However, most of the mutations of",
"    <em>",
"     VHL",
"    </em>",
"    genes are associated with tumors characteristic of",
"    <em>",
"     VHL",
"    </em>",
"    tumor predisposition syndrome and not congenital polycythemia, although in some instances an acquired polycythemia from the EPO produced by tumor is encountered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An animal model, which recapitulates Chuvash polycythemia in the mouse, has been developed using the above-noted R200W",
"    <em>",
"     VHL",
"    </em>",
"    gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/46\">",
"     46",
"    </a>",
"    ]. The activity of HIF proteins, specifically the HIF-2 alpha isoform, was upregulated in this animal model. This and other observations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/47-52\">",
"     47-52",
"    </a>",
"    ] suggest that it is HIF-2 alpha, rather than HIF-1 alpha, that is the dominant isoform operative in EPO gene regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Hypoxia inducible factor 2 gene mutation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Proline hydroxylase gene mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mutation in one of the proline hydroxylases (PHD2, prolyl hydroxylase domain protein 2,",
"    <em>",
"     EGLN1",
"    </em>",
"    gene) involved in the degradation of HIF1-alpha under normoxic conditions has been found in a family with autosomal dominant erythrocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/54\">",
"     54",
"    </a>",
"    ]. A separate study of 67 patients with spontaneous or familial isolated erythrocytosis identified three novel mutations in the catalytic domain of the PHD2 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/55\">",
"     55",
"    </a>",
"    ]. All were germ-line, heterozygous, and missense loss-of-function mutations, and coded for a predicted full-length mutant PHD2 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 34 polycythemic patients who did not fulfill WHO diagnostic criteria for polycythemia vera, five PHD2 variants were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/44\">",
"     44",
"    </a>",
"    ]. Functional comparative studies of the ability of these PHD2 mutants to regulate the activity, stability, and hydroxylation of HIF alpha indicated that two categories could be distinguished. The first was associated with a weak deficiency in HIF alpha regulation, while the second had a more deleterious effect. Of interest, and in common with mutations in the VHL gene as discussed above, mutations in the first category were associated with polycythemia, while those in the second category were associated with polycythemia as well as tumor formation. In this case the tumor was a paraganglioma, a tumor originating from neural crest cells similar to pheochromocytoma, but with an extra-adrenal localization.",
"   </p>",
"   <p>",
"    Of interest, an orally active inhibitor of HIF-prolyl hydroxylase has been shown to increase EPO production and stimulate erythropoiesis in mouse and primate models [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/56\">",
"     56",
"    </a>",
"    ], and conditional inactivation or deletion of PHD2 in mice leads to erythrocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Such inhibitors are currently being tested in the clinical setting as a potential treatment for anemia, including anemia secondary to chronic renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, as PHD2 manipulations activate many other genes, such inhibitors might have unintended deleterious effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link&amp;anchor=H20#H20\">",
"     \"Introduction to recombinant hematopoietic growth factors\", section on 'EPO mimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypoxia inducible factor 2 gene mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant erythrocytosis has been described in a number of families due to a gain-of-function mutation in the HIF2-alpha gene, rendering the HIF2-alpha protein less susceptible to hydroxylation by PHD2 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/47,62,63\">",
"     47,62,63",
"    </a>",
"    ]. Affected individuals usually present with congenital erythrocytosis and with elevated or inappropriately normal EPO levels considering their elevated hematocrit. While the relative contributions of HIF1-alpha and HIF2-alpha to hypoxia-driven gene expression of EPO is still an area of intense investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/64\">",
"     64",
"    </a>",
"    ], the existence of these subjects substantiates a central role for HIF2-alpha in the regulation of EPO synthesis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'von Hippel Lindau gene mutation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Somatic gain-of-function mutations in the gene encoding",
"    <em>",
"     HIF2-alpha",
"    </em>",
"    were found in two patients, one with paraganglioma and the other with paraganglioma and somatostatinoma, both of whom had polycythemia since birth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/65\">",
"     65",
"    </a>",
"    ]. The mutations in both cases were in the vicinity of the primary hydroxylation site of the HIF2 alpha protein, leading to increased HIF2-alpha activity and increased protein half-life. While the mutations were found in the patients&rsquo; tumors at multiple non-metastatic sites, but not in the DNA from samples of blood, urine, serum, nails, or buccal mucosa, the presence of life-long polycythemia suggests that somatic mutations were present during embryogenesis in precursor cells secreting excess erythropoietin, resulting in the early onset of polycythemia, before gross tumor formation.",
"   </p>",
"   <p>",
"    In another report, a polycythemic patient with a novel germline",
"    <em>",
"     HIF2-alpha",
"    </em>",
"    gene",
"    <sup>",
"    </sup>",
"    mutation inherited from his mother also developed recurrent",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/66\">",
"     66",
"    </a>",
"    ]. This underscores the",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma-promoting",
"    </span>",
"    potential of gain-of-function mutations of",
"    <em>",
"     HIF2A",
"    </em>",
"    that alone, either as somatic or germline mutations, can contribute to, but are not sufficient for,",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER POLYCYTHEMIAS WITH DEFINED MOLECULAR LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other polycythemias with defined molecular lesions include the high oxygen affinity hemoglobin mutants, congenital methemoglobinemia, and 2,3-bisphosphoglycerate (2,3-BPG) deficiency. The first two disorders, which are associated with increased hemoglobin oxygen affinity, are discussed in detail elsewhere and will be only briefly reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     High oxygen affinity hemoglobin mutants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital polycythemias due to high oxygen affinity hemoglobin mutants were the first congenital polycythemias defined, but are an uncommon cause of congenital polycythemia. Mutations of both alpha and beta globin genes have been described that lead to autosomal dominant polycythemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hemoglobin tetramer oscillates between the R (relaxed; fully oxygenated hemoglobin) and T (tense; fully deoxygenated hemoglobin) states of the quaternary protein conformation, requiring the cooperative interaction of globin subunits. Single point substitutions, double point substitutions, deletions, insertions, reading frame shift mutations, and fusion genes can all result in hemoglobins with increased oxygen affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/1\">",
"     1",
"    </a>",
"    ]. Underlying all known high ligand affinity hemoglobin mutants is the furtherance of the R state, or high affinity conformer of the hemoglobin molecule. This can occur by stabilizing the R state or destabilizing the T state (low affinity conformer). The molecular basis of this change can be:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alteration in areas of the molecule directly involved in the R&mdash;&gt;T transition, such as in Hb Chesapeake and Hb Montefiore",
"     </li>",
"     <li>",
"      A change of the alpha 1 beta 1 interface, such as in Hb Crete; this interface is not normally dissociable and does not participate in the R&mdash;&gt;T conformational change",
"     </li>",
"     <li>",
"      A mutation reducing the affinity of the hemoglobin for 2,3-BPG, such as is seen in Hb Rahere and Hb Providence",
"     </li>",
"     <li>",
"      A mutation constraining the molecule through limited polymerization (not Hb S)",
"     </li>",
"     <li>",
"      Elongation of chains by termination codon or frame-shift mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete listing of high affinity hemoglobins can be found on the Globin Gene Server on the Internet (",
"    <a class=\"external\" href=\"file://globin.cse.psu.edu/\">",
"     globin.cse.psu.edu",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The functional consequence of this change in oxygen affinity is decreased delivery of oxygen to the peripheral tissues and compensatory polycythemia. Regardless of the mechanism, affected patients are generally asymptomatic, since compensatory polycythemia maintains normal tissue oxygen delivery.",
"   </p>",
"   <p>",
"    There is considerable variation in the age at diagnosis. Among patients with polycythemia, a red cell defect, such as a high oxygen affinity hemoglobin, should be considered in those who have an inappropriately normal or an elevated serum EPO concentration and a normal partial pressure of oxygen and oxygen saturation. The red cell oxygen equilibrium curve should be the benchmark for diagnosis. An accurate p50 value",
"    <strong>",
"     cannot",
"    </strong>",
"    be \"calculated\" from",
"    <strong>",
"     arterial",
"    </strong>",
"    pO2 data as is often done. Both the saturation of hemoglobin and pO2 from",
"    <strong>",
"     venous",
"    </strong>",
"    blood must be directly measured to estimate an informative p50 in these patients (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 3",
"    </a>",
"    ). The hemox-analyzer apparatus is needed when accurate p50 and Hill coefficients are needed, but this equipment is often not readily available for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, an oxygen equilibrium curve of the dialyzed hemolysate may be obtained to exclude cytosol effects on ligand binding (such as a genetic reduction in 2,3-BPG). If this is not possible, the red cell oxygen equilibrium curve can be remeasured in 2,3-BPG depleted red cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital methemoglobinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the formation of oxyhemoglobin from deoxyhemoglobin and molecular oxygen, one electron is partially transferred from heme iron to the bound oxygen, forming a ferric-superoxide anion complex",
"    <span class=\"nowrap\">",
"     (Fe3+/O2-).",
"    </span>",
"    During deoxygenation, most of the oxygen leaves the molecule as molecular oxygen, but a small amount leaves as a superoxide (O2-) radical. In the latter circumstance, the partially transferred electron is not returned to the iron moiety, leaving the iron in the ferric state and forming methemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     HbFe2+/O2",
"    </span>",
"    &nbsp; &mdash;&gt; &nbsp; HbFe3+ &nbsp; + &nbsp; O2-",
"   </p>",
"   <p>",
"    Autooxidation of hemoglobin to methemoglobin occurs spontaneously at a slow rate in normal individuals, converting 0.5 to 3 percent of the available hemoglobin to methemoglobin per day. The only physiologically important pathway for reducing methemoglobin back to hemoglobin is the NADH-dependent reaction catalyzed by cytochrome b5 reductase (b5R). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"     \"Genetics and pathogenesis of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ferric hemes of methemoglobin are",
"    <strong>",
"     unable",
"    </strong>",
"    to bind oxygen. In addition, the oxygen affinity of any accompanying ferrous hemes in the hemoglobin tetramer is increased; as a result, the oxygen dissociation curve is \"left-shifted\" and oxygen delivery to the tissues is impaired, leading to a compensatory polycythemia to maintain normal tissue oxygen delivery (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major cause of hereditary methemoglobinemia is a deficiency of cytochrome b5 reductase. Less common causes are hemoglobin M disease, in which there is a mutated globin, and cytochrome b5 deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"     \"Genetics and pathogenesis of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with congenital methemoglobinemia are asymptomatic (although some complain of headache and easy fatigue) even with methemoglobin levels as high as 40 percent of total hemoglobin. Their main complaint is \"cyanosis\" or slate-blue color of the skin and mucous membranes, a finding that is due to the different absorbance spectrum of methemoglobin compared with oxyhemoglobin. The laboratory diagnosis of methemoglobinemia is based upon analysis of its absorption spectrum, which has peak absorbance at 631 nm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     2,3-bisphosphoglycerate deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extremely rare cause of congenital secondary polycythemia is familial 2,3-BPG (previously known as 2,3-DPG) deficiency, which results from a deficiency of the red cell enzyme bisphosphoglyceromutase (BPGM) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The ensuing increase in hemoglobin oxygen affinity decreases the amount of oxygen released peripherally, leading to compensatory polycythemia.",
"   </p>",
"   <p>",
"    Only one family with this deficiency has been comprehensively studied [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The proband with polycythemia had undetectable BPGM activity and 2,3-BPG levels; his children were not polycythemic, a finding compatible with an autosomal recessive disease. Subsequent studies have shown that the virtual absence of BPGM activity in the proband and three sisters was due to compound heterozygosity for mutations in the BPGM gene [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/71\">",
"     71",
"    </a>",
"    ]. However, the children had partially reduced enzyme activity and mildly decreased 2,3-BPG levels reflected in a reduced P50. Other heterozygous progeny of this enzyme-deficient patient, as well as several heterozygous subjects from unrelated families, were later found to have moderate polycythemia, casting doubt on the autosomal recessive mode of its inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the rarity of complete BPGM deficiency, it is not possible to predict the phenotype of heterozygous individuals. Finding a decreased P50 is a prerequisite for consideration of 2,3-BPG deficiency as a cause of congenital polycythemia (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 3",
"    </a>",
"    ). In comparison to the high oxygen affinity hemoglobins, the oxygen affinity of the dialyzed hemolysate is normal and the level of 2,3-BPG is very low in familial 2,3-BPG deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Primary familial and congenital polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary familial and congenital polycythemia (PFCP, also called benign erythrocytosis and autosomal dominant erythrocytosis) is an uncommon cause of polycythemia but is more prevalent than 2,3-BPG deficiency. It is typically inherited as an autosomal dominant (or less frequently sporadic) disorder. Its characteristics are defined in greater detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/18,20,72-74\">",
"     18,20,72-74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An elevated erythrocyte mass and hemoglobin concentration",
"     </li>",
"     <li>",
"      Hypersensitivity of erythroid progenitors to EPO in serum-containing clonogenic cultures",
"     </li>",
"     <li>",
"      Low serum EPO concentrations",
"     </li>",
"     <li>",
"      A normal hemoglobin-oxygen dissociation curve",
"     </li>",
"     <li>",
"      Absence of progression to acute leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In searching for the molecular lesion resulting in the PFCP phenotype, abnormalities of EPO or its receptor (EPOR) were considered likely candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/72\">",
"     72",
"    </a>",
"    ]. As mentioned above, gain-of-function EPOR mutations have only been demonstrated in a small number of patients with primary familial and congenital polycythemia (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. All EPOR mutations associated with this disorder have a truncated receptor that lacks the C-terminal negative regulatory domain of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/20,75\">",
"     20,75",
"    </a>",
"    ]. Thus, the lack of binding site for the negative regulator hematopoietic phosphatase (HCP) triggers",
"    <span class=\"nowrap\">",
"     proliferation-inducing/apoptosis-inhibiting",
"    </span>",
"    pathways that contribute to the polycythemia. The development of polycythemia has been replicated in a mouse model in which the mouse gene was replaced by a disease-causing human EPOR gene [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors also appear to be involved in patients with EPOR mutations. In one family, a child in the third generation inherited the EPOR mutated gene with in vitro hyperresponsiveness to EPO but did not have polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/77\">",
"     77",
"    </a>",
"    ]. Thus, unidentified epigenetic factors can mask a full phenotypic expression of an EPOR gene mutation.",
"   </p>",
"   <p>",
"    However, EPOR mutations are an infrequent cause of PFCP. In one analysis of 53 unrelated subjects, for example, only five EPOR mutations were identified (9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/20,78\">",
"     20,78",
"    </a>",
"    ]. It has been suggested that a dominant lesion at an as yet unidentified gene, involving either the EPOR-signaling pathway or another erythropoiesis-regulating pathway, is responsible for the enhanced proliferation of erythroid progenitors in response to EPO in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     POLYCYTHEMIAS WITH INCOMPLETELY DEFINED MOLECULAR LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to patients with PFCP who do not have an EPOR gene mutation, the other major congenital polycythemias in which the molecular lesion is incompletely defined include those with congenital elevation of EPO and normal to increased responsiveness of erythroid progenitors to EPO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POLYCYTHEMIA VERA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia vera (PV) is the most common of the primary polycythemias. As with the other Philadelphia chromosome negative chronic myeloproliferative neoplasms (essential thrombocythemia, chronic myeloid leukemia, and primary myelofibrosis), PV, unlike chronic myeloid leukemia, is caused by more than one genetic event (at least two of these being acquired somatic mutations) in a single hematopoietic progenitor that leads to an increase in red cell production and a variable increase of platelets and myeloid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Major progress in elucidating the identity of the affected gene(s) and the nature of the disease-causing mutation responsible for PV was made in 2005 (ie, the",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/80\">",
"     80",
"    </a>",
"    ]. The significance of this discovery and its limitations as not being the sole factor responsible for PV will be discussed here in relation to the cellular biology of PV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycythemia vera arises from a single hematopoietic progenitor; as a result, virtually all of the vast majority of the circulating myeloid cells are clonal in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/81\">",
"     81",
"    </a>",
"    ]. The mutational event leading to clonal myeloid expansion in PV affects the pluripotent stem cell, since a variable proportion of B-lymphocytes are a part of the PV clone. However, the majority of T-cells and natural killer cells remain polyclonal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/82\">",
"     82",
"    </a>",
"    ]. These observations provide a background for studies designed to characterize the primary PV defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     In vitro responses of PV progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first in vitro abnormality in PV progenitor cells was the observation that these cells form erythroid colonies in the absence of exogenous EPO, a phenomenon not observed in progenitor cells from normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/83\">",
"     83",
"    </a>",
"    ]. This observation has been widely used as a diagnostic assay to help distinguish PV from other causes of polycythemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/21,84-86\">",
"     21,84-86",
"    </a>",
"    ]. The presence of erythroid colonies in the absence of exogenous EPO, variously called spontaneous, EPO-independent, or endogenous erythroid colonies (EECs), is the hallmark of PV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This test can be readily performed on cultures of peripheral blood progenitor cells; bone marrow aspiration is not required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/1,86-88\">",
"     1,86-88",
"    </a>",
"    ]. The erythroid colony assay is a useful tool for distinguishing PV from secondary polycythemias, and has helped characterize primary familial and congenital polycythemia (PFCP) as a separate disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/18,73,89\">",
"     18,73,89",
"    </a>",
"    ]. In PV, EECs form in the absence of added EPO in serum-containing tissue cultures, whereas no or few EEC are present in PFCP or Chuvash polycythemia, conditions in which the erythroid progenitors are hypersensitive to the presence of EPO. In addition, neutralizing antibodies directed against EPO or the EPOR eliminate or markedly inhibit erythroid colony formation in PFCP and normal subjects, but not EEC in PV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/20,90\">",
"     20,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations and on our experience, the EEC assay is the most sensitive of all assays used for the diagnosis of PV, especially in those patients lacking the full PV phenotype or the",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. Interestingly, some patients presenting with an essential thrombocythemia phenotype have EEC, but on careful follow-up they have typically progressed to PV. The EEC assay is performed in clonogenic cultures containing serum and serum-component proteins. When rigorous serum-free conditions are used, BFU-Es from patients with PV also show markedly increased sensitivity to IGF-I [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/93\">",
"     93",
"    </a>",
"    ]. This hypersensitivity occurs via the IGF-I receptor, which is hyperphosphorylated under basal conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/94\">",
"     94",
"    </a>",
"    ]; however, this assay is technically difficult and not routinely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other possible mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional pathophysiologic mechanisms leading to PV have been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A finding of particular interest is overexpression of the PRV-1 gene, a novel member of the urokinase-type plasminogen activator receptor superfamily [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/95\">",
"       95",
"      </a>",
"      ]. The mRNA for this gene was found in granulocytes of patients with PV and some patients with essential thrombocythemia, and not in subjects with secondary polycythemia due to pulmonary disease. Granulocytes of normal subjects have apparently normal levels of the peptide product of this gene. This gene does not appear to be mutated in PV. Its continuous transcription in the terminally differentiated myeloid cells appears to be a secondary phenomenon and is of no practical value in the diagnosis and management of PV patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link&amp;anchor=H27#H27\">",
"       \"Diagnostic approach to the patient with suspected polycythemia vera\", section on 'Investigational diagnostic methods'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Previous studies of familial clustering of PV have suggested that loss of heterozygosity (LOH) might play a role in disease pathogenesis. A genome-wide screening for LOH using microsatellite markers with approximately 10 cM average spacing was performed and 9pLOH was detected in approximately 33 percent of PV subjects. This finding represents the most frequent chromosomal lesion described in PV thus far. However, the 9pLOH is due to mitotic recombination and remains undetectable by cytogenetic analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/92,98\">",
"     92,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Familial PV",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are rare instances of a familial incidence of PV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. In some families, the predisposition for PV is inherited as an autosomal dominant trait, along with clonal hematopoiesis in asymptomatic family members. However, clinical PV in these families is acquired as a new mutation, occasionally at a younger age than seen in sporadic PV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/101\">",
"     101",
"    </a>",
"    ]. This observation suggests that, at least in these families, the disease may be due to loss of heterozygosity and may result from a combination of an inherited germline mutation followed by a \"second hit\" somatic mutation that leads to a clonal hematopoiesis.",
"   </p>",
"   <p>",
"    Whether the acquired and inherited mutations are due to DNA sequence changes or hereditable changes of",
"    <span class=\"nowrap\">",
"     DNA/histone",
"    </span>",
"    confirmation, such as those conferred by",
"    <span class=\"nowrap\">",
"     methylation/acetylation",
"    </span>",
"    of DNA and or histone (epigenetic changes) is a subject of active studies. This conclusion is further supported by the fact that the 9pLOH does not segregate with the PV phenotype, indicating that the molecular defect of PV is caused by more than one",
"    <span class=\"nowrap\">",
"     genetic/epigenetic",
"    </span>",
"    event [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     JAK2 (JAK2V617F) mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    signaling plays a pivotal role in cellular proliferation and cell survival [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/102,103\">",
"     102,103",
"    </a>",
"    ], in particular in EPO-EPOR signaling in erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/104\">",
"     104",
"    </a>",
"    ]. JAK2 deficiency in mice is embryonic lethal due to the absence of definitive erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. In addition,",
"    <span class=\"nowrap\">",
"     JAK2-/-",
"    </span>",
"    fetal liver myeloid progenitors fail to respond to several hematopoietic growth factors including EPO [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/105\">",
"     105",
"    </a>",
"    ]. JAK2 mutations have been reported to be associated with some cases of T-ALL, B-ALL, and atypical CML [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/106,107\">",
"     106,107",
"    </a>",
"    ], encoding for an oncogenic chimeric protein with constitutive activation of the JAK2 tyrosine kinase (TK) domain. These findings documented that JAK2 has an oncogenic potential.",
"   </p>",
"   <p>",
"    Abnormal signaling in PV through JAK2 was first proposed in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/108\">",
"     108",
"    </a>",
"    ], followed by the finding of a single nucleotide JAK2 somatic mutation (",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation) in the majority of PV patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/109\">",
"     109",
"    </a>",
"    ], confirmed by four separate studies, published in rapid succession [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/110-113\">",
"     110-113",
"    </a>",
"    ]. This single nucleotide change was shown to emulate many properties of native PV erythroid progenitors, including EPO independence and hypersensitivity of PV erythroid colonies. This mutation was predicted to dysregulate TK activity by disrupting the JH2 inhibitory regulation of JAK2, allowing the enzyme constitutive tyrosine phosphorylation activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/109-112\">",
"     109-112",
"    </a>",
"    ]. Mutated JAK2 could then bind to a receptor, recruit and phosphorylate STATs in the complete absence, or in the presence of trace amounts of hematopoietic growth factors.",
"   </p>",
"   <p>",
"    The",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation was also shown to be necessary for EPO hypersensitivity of PV progenitors and formation of EEC in in vitro cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/109-112\">",
"     109-112",
"    </a>",
"    ]. The most direct evidence connecting this JAK2 mutation to PV phenotype was provided when the mutant gene was expressed in mouse models; transplanted mice exhibited a clinical phenotype closely resembling PV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/109,114-116\">",
"     109,114-116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, the elegant transgenic studies with different levels of expression of mutated",
"    <em>",
"     JAK2",
"    </em>",
"    V617F differentiated among ET, PV and PMF phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A duplication of the mutant allele, as a result of previously reported mitotic recombination, resulting in so-called uniparental disomy has been found in a subset of PV myeloid cells and progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/98\">",
"     98",
"    </a>",
"    ]. The existence of homozygosity for the",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation suggests that it confers a further selective proliferative advantage for the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/118\">",
"     118",
"    </a>",
"    ], perhaps through its interactions with SOCS3 (suppressor of cytokine signaling 3) and the EPO receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/119\">",
"     119",
"    </a>",
"    ]. The",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation is acquired preferentially on a specific constitutional JAK2 haplotype named",
"    <span class=\"nowrap\">",
"     46/1,",
"    </span>",
"    and this haplotype predisposes to development of both",
"    <em>",
"     JAK2",
"    </em>",
"    V617F as well as JAK2 exon 12 mutations (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/120\">",
"     120",
"    </a>",
"    ]. However, this haplotype cannot be a PV initiating lesion, although its presence makes the acquired",
"    <em>",
"     JAK2",
"    </em>",
"    V617F somatic mutation more likely. While it is of intense theoretical and research interest, it has no clinically relevant value at the present time and there is no need to establish its presence or absence for optimal care of individual PV patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169713\">",
"    <span class=\"h2\">",
"     JAK2 exon 12 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some of the rare PV patients who are",
"    <em>",
"     JAK2",
"    </em>",
"    V617F-negative, other JAK2 mutations have been identified in exon 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Unlike the",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation, these are heterogeneous and are located within approximately 20 nucleotides and are comprised of missense, stop codon, insertion and deletion mutations. As their allele burden is often low, they are not always easily detectable by conventional techniques such as DNA sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, many questions remain concerning the significance of this finding (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'JAK2 mutations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant proportion of patients with primary myelofibrosis or essential thrombocythemia also have this mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/109-112\">",
"       109-112",
"      </a>",
"      ]. It is not clear whether or not these patients represent a variant of PV or whether this mutation acts in concert with other somatic changes, leading to multiple hematopoietic phenotypes.",
"     </li>",
"     <li>",
"      In one study, 5 percent of 101 patients with myelodysplastic syndrome and some patients with chronic myelomonocytic and neutrophilic leukemias were also shown to have this mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/124\">",
"       124",
"      </a>",
"      ]. A separate analysis of 325 patients with various hematological malignancies has confirmed these findings [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      This mutation has also been found in 25 percent of patients with Ph-negative chronic myeloid leukemia, 18 percent of patients with megakaryocytic leukemia, but only in 5 of 10 patients with acute myeloid leukemia and antecedent PV [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/125\">",
"       125",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is growing evidence from studies in patients with sporadic PV as well as familial myeloproliferative disorders that this JAK2 mutation is not the PV-originating somatic mutation, but rather represents a late secondary change occurring in a clone initiated by an as yet unidentified genetic change(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/118,126,127\">",
"     118,126,127",
"    </a>",
"    ]. Nevertheless, this is clearly the most important discovery in our understanding of PV pathophysiology [",
"    <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/79\">",
"     79",
"    </a>",
"    ]. This mutation also provides an obvious target for drug discovery, with the hope of reproducing the success of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in CML.",
"   </p>",
"   <p>",
"    Several JAK2 inhibitors have been developed and tested in clinical trials and have been demonstrated to be of clinical benefit in PV, and especially in primary and secondary myelofibrosis. The first of these,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/35/29239?source=see_link\">",
"     ruxolitinib",
"    </a>",
"    , is FDA approved for use in primary myelofibrosis. While it decreases symptoms and partially ameliorates splenomegaly, there is little evidence that it changes the biology of the disease and marrow histopathology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the myeloproliferative neoplasms\", section on 'JAK2 mutations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=see_link&amp;anchor=H28#H28\">",
"     \"Prognosis and treatment of primary myelofibrosis\", section on 'JAK2 inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1169732\">",
"    <span class=\"h2\">",
"     Additional mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional mutations that are encountered with moderate frequency in PV and other Philadelphia chromosome negative myeloproliferative disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations of genes that often facilitate",
"      <em>",
"      </em>",
"      JAK2 or STAT5 signal transduction, such as:",
"      <em>",
"       LNK,",
"      </em>",
"      <em>",
"       TET2",
"      </em>",
"      ,",
"      <em>",
"       CBL",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/128\">",
"       128",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mutations of genes that modulate epigenetic composition of genomic DNA (DNA and histone methylation and histone acetylation):",
"      <em>",
"       EZH2, TET2, ASXL1, JAK2",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/129\">",
"       129",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mutations in genes of the spliceosome machinery:",
"      <em>",
"       SF3B1, SRSF2, U2AF1",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/17/29978/abstract/130,131\">",
"       130,131",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these mutations appears to be a consistent PV-initiating pre-",
"    <em>",
"     JAK2",
"    </em>",
"    V617F mutation. Furthermore, these mutations have little diagnostic impact, owing to both their low specificity and frequency. However, they have a prognostic role, as shown for",
"    <em>",
"     EZH2",
"    </em>",
"    in primary myelofibrosis and p53 alterations at the time of leukemic transformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5555814\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital polycythemias are conditions associated with life-long increases in red blood cell mass secondary to the stimulation of erythropoiesis by mutations that affect the interaction of hemoglobin with oxygen or the various components of the hypoxia-sensing pathway (",
"    <a class=\"graphic graphic_figure graphicRef53801 \" href=\"UTD.htm?3/26/3503\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Regulation of erythropoiesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alterations in hemoglobin oxygen affinity  These include high oxygen affinity hemoglobin mutants, congenital methemoglobinemia, and 2,3-bisphosphoglycerate deficiency. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other polycythemias with defined molecular lesions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"       \"Genetic disorders of hemoglobin oxygen affinity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"       \"Genetics and pathogenesis of methemoglobinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alterations in hypoxia sensing  These include mutations involving the von Hippel Lindau gene (Chuvash polycythemia) or the more rare mutations of proline hydroxylase or hypoxia inducible factor 2. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Congenital polycythemias with augmented hypoxia sensing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polycythemias with undefined lesions  These include the autosomal dominant and recessive familial polycythemias and familial polycythemia vera. Alterations of the erythropoietin receptor have been documented in some families, but in most cases the mechanism is unknown. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Polycythemias with incompletely defined molecular lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Familial PV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/1\">",
"      Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/2\">",
"      Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/3\">",
"      Stopka T, Zivny JH, Stopkova P, et al. Human hematopoietic progenitors express erythropoietin. Blood 1998; 91:3766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/4\">",
"      Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/5\">",
"      Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/6\">",
"      Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/7\">",
"      Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/8\">",
"      Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/9\">",
"      Yoon D, Ponka P, Prchal JT. Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol 2011; 300:C1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/10\">",
"      Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008; 105:19579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/11\">",
"      Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/12\">",
"      Keith B, Johnson RS, Simon MC. HIF 1alpha and HIF 2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/13\">",
"      Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood 1990; 76:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/14\">",
"      Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/15\">",
"      D'Andrea AD, Yoshimura A, Youssoufian H, et al. The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol 1991; 11:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/16\">",
"      Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/17\">",
"      Klingm&uuml;ller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/18\">",
"      Gregg XT, Prchal JT. Erythropoietin receptor mutations and human disease. Semin Hematol 1997; 34:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/19\">",
"      Arcasoy MO, Degar BA, Harris KW, Forget BG. Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene. Blood 1997; 89:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/20\">",
"      Kralovics R, Indrak K, Stopka T, et al. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997; 90:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/21\">",
"      Prchal JT. Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 2003; 17:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/22\">",
"      Sawada K, Krantz SB, Dessypris EN, et al. Human colony-forming units-erythroid do not require accessory cells, but do require direct interaction with insulin-like growth factor I and/or insulin for erythroid development. J Clin Invest 1989; 83:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/23\">",
"      Correa PN, Axelrad AA. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of insulinlike growth factor 1. Blood 1991; 78:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/24\">",
"      Shih LY, Huang JY, Lee CT. Insulin-like growth factor I plays a role in regulating erythropoiesis in patients with end-stage renal disease and erythrocytosis. J Am Soc Nephrol 1999; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/25\">",
"      Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/26\">",
"      Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/27\">",
"      Gossmann J, Th&uuml;rmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/28\">",
"      Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995; 10:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/29\">",
"      Mrug M, Stopka T, Julian BA, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/30\">",
"      Marrero MB, Schieffer B, Paxton WG, et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/31\">",
"      Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med 2010; 2:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/32\">",
"      Poliakova LA. [Familial erythrocytosis among the residents of the Chuvash ASSR]. Probl Gematol Pereliv Krovi 1974; 19:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/33\">",
"      Sergeyeva A, Gordeuk VR, Tokarev YN, et al. Congenital polycythemia in Chuvashia. Blood 1997; 89:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/34\">",
"      Pastore YD, Jelinek J, Ang S, et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003; 101:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/35\">",
"      Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 2003; 73:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/36\">",
"      Percy MJ, McMullin MF, Jowitt SN, et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood 2003; 102:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/37\">",
"      Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica 2005; 90:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/38\">",
"      Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood 2006; 107:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/39\">",
"      Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004; 103:3924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/40\">",
"      Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002; 32:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/41\">",
"      Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood 2011; 118:5278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/42\">",
"      Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/43\">",
"      Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis 2002; 28:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/44\">",
"      Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica 2012; 97:9.",
"     </a>",
"    </li>",
"    <li>",
"     Prchal JT. Clinical manifestations and classification of erythrocyte disorders. In: Williams Hematology, 8th ed, Kaushansky K, Lichtman MA, Kipps TJ, et al.  (Eds), McGraw Hill, New York 2010. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/46\">",
"      Hickey MM, Lam JC, Bezman NA, et al. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. J Clin Invest 2007; 117:3879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/47\">",
"      Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/48\">",
"      Percy MJ, Sanchez M, Swierczek S, et al. Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2 alpha iron-responsive element? Blood 2007; 110:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/49\">",
"      Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 2007; 117:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/50\">",
"      Gruber M, Hu CJ, Johnson RS, et al. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A 2007; 104:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/51\">",
"      Hickey MM, Richardson T, Wang T, et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest 2010; 120:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/52\">",
"      Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 2010; 116:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/53\">",
"      van Rooijen E, Voest EE, Logister I, et al. Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia. Blood 2009; 113:6449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/54\">",
"      Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A 2006; 103:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/55\">",
"      Albiero E, Ruggeri M, Fortuna S, et al. Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Haematologica 2012; 97:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/56\">",
"      Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007; 110:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/57\">",
"      Minamishima YA, Moslehi J, Bardeesy N, et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008; 111:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/58\">",
"      Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008; 111:3229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/59\">",
"      Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/60\">",
"      Querbes W, Bogorad RL, Moslehi J, et al. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood 2012; 120:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/61\">",
"      Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008; 359:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/62\">",
"      Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 2008; 111:5400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/63\">",
"      Gale DP, Harten SK, Reid CD, et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood 2008; 112:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/64\">",
"      Eltzschig HK, El Kasmi KC, Eckle T. The HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/65\">",
"      Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012; 367:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/66\">",
"      Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 2013; 91:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/67\">",
"      Agarwal N, Mojica-Henshaw MP, Simmons ED, et al. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci 2007; 4:232.",
"     </a>",
"    </li>",
"    <li>",
"     Agarwal N, Nagel RL, Prchal JT. Dyshemoglobinemias. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed, Steinberg M (Ed), Cambridge UP, Cambridge 2009. p.607.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/69\">",
"      Rosa R, Prehu MO, Beuzard Y, Rosa J. The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest 1978; 62:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/70\">",
"      Galacteros F, Rosa R, Prehu MO, et al. [Diphosphoglyceromutase deficiency: new cases associated with erythrocytosis]. Nouv Rev Fr Hematol 1984; 26:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/71\">",
"      Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood 1992; 80:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/72\">",
"      Emanuel PD, Eaves CJ, Broudy VC, et al. Familial and congenital polycythemia in three unrelated families. Blood 1992; 79:3019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/73\">",
"      Juvonen E, Ikkala E, Fyhrquist F, Ruutu T. Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991; 78:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/74\">",
"      Huang LJ, Shen YM, Bulut GB. Advances in understanding the pathogenesis of primary familial and congenital polycythaemia. Br J Haematol 2010; 148:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/75\">",
"      Damen JE, Krosl J, Morrison D, et al. The hyperresponsiveness of cells expressing truncated erythropoietin receptors is contingent on insulin-like growth factor-1 in fetal calf serum. Blood 1998; 92:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/76\">",
"      Divoky V, Liu Z, Ryan TM, et al. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci U S A 2001; 98:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/77\">",
"      Kralovics R, Sokol L, Prchal JT. Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia. J Clin Invest 1998; 102:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/78\">",
"      Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol 2001; 68:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/79\">",
"      Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/80\">",
"      Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/81\">",
"      Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/82\">",
"      Prchal JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 2005; 12:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/83\">",
"      Prchal JF, Axelrad AA. Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 1974; 290:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/84\">",
"      Weinberg RS. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/85\">",
"      Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk Lymphoma 1996; 22 Suppl 1:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/86\">",
"      Shih LY, Lee CT, See LC, et al. In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. Eur J Clin Invest 1998; 28:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/87\">",
"      Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 1994; 83:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/88\">",
"      Zanjani ED, Lutton JD, Hoffman R, Wasserman LR. Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J Clin Invest 1977; 59:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/89\">",
"      Prchal JT, Crist WM, Goldwasser E, et al. Autosomal dominant polycythemia. Blood 1985; 66:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/90\">",
"      Fisher MJ, Prchal JF, Prchal JT, D'Andrea AD. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/91\">",
"      Liu E, Jelinek J, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101:3294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/92\">",
"      Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/93\">",
"      Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994; 83:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/94\">",
"      Mirza AM, Ezzat S, Axelrad AA. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood 1997; 89:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/95\">",
"      Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 2000; 95:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/96\">",
"      Klippel S, Strunck E, Busse CE, et al. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood 2002; 100:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/97\">",
"      Caruccio L, Bettinotti M, Director-Myska AE, et al. The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles of a single gene, CD177, in chromosome band 19q13.31. Transfusion 2006; 46:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/98\">",
"      Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/99\">",
"      Miller RL, Purvis JD 3rd, Weick JK. Familial polycythemia vera. Cleve Clin J Med 1989; 56:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/100\">",
"      Brubaker LH, Wasserman LR, Goldberg JD, et al. Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. Am J Hematol 1984; 16:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/101\">",
"      Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102:3793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/102\">",
"      Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/103\">",
"      Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006; 134:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/104\">",
"      Neubauer H, Cumano A, M&uuml;ller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/105\">",
"      Damen JE, Wakao H, Miyajima A, et al. Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and Stat5 activation. EMBO J 1995; 14:5557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/106\">",
"      Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997; 278:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/107\">",
"      Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/108\">",
"      Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/109\">",
"      James C, Ugo V, Le Cou&eacute;dic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/110\">",
"      Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/111\">",
"      Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/112\">",
"      Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/113\">",
"      Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/114\">",
"      Wernig G, Mercher T, Okabe R, et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107:4274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/115\">",
"      Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/116\">",
"      Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115:3589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/117\">",
"      Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008; 111:3931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/118\">",
"      Bellann&eacute;-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/119\">",
"      Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007; 109:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/120\">",
"      Pietra D, Casetti I, Da Vi&agrave; MC, et al. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. Am J Hematol 2012; 87:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/121\">",
"      Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/122\">",
"      Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/123\">",
"      Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011; 86:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/124\">",
"      Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \"atypical\" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/125\">",
"      Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G&gt;T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106:3370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/126\">",
"      Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/127\">",
"      Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/128\">",
"      Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/129\">",
"      Vannucchi AM, Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011; 96:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/130\">",
"      Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119:3203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/17/29978/abstract/131\">",
"      Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012; 119:4480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7106 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-BECC0B612A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29978=[""].join("\n");
var outline_f29_17_29978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5555814\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REGULATION OF ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oxygen sensor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Erythropoietin receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Insulin-like growth factor-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONGENITAL POLYCYTHEMIAS WITH AUGMENTED HYPOXIA SENSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chuvash Polycythemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      von Hippel Lindau gene mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Proline hydroxylase gene mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypoxia inducible factor 2 gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER POLYCYTHEMIAS WITH DEFINED MOLECULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      High oxygen affinity hemoglobin mutants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      2,3-bisphosphoglycerate deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Primary familial and congenital polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      POLYCYTHEMIAS WITH INCOMPLETELY DEFINED MOLECULAR LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POLYCYTHEMIA VERA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      In vitro responses of PV progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other possible mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Familial PV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      JAK2 (JAK2V617F) mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169713\">",
"      JAK2 exon 12 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1169732\">",
"      Additional mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5555814\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7106|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12799\" title=\"figure 1\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/26/3503\" title=\"figure 2\">",
"      Oxygen sensor model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 3\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7106|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/46/31468\" title=\"table 1\">",
"      Causes of erythrocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24777?source=related_link\">",
"      Diagnostic approach to the patient with polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36922?source=related_link\">",
"      Prognosis and treatment of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_17_29979="Cystic hygroma outcome";
var content_f29_17_29979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Expected outcomes for first trimester cystic hygroma and increased nuchal translucency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cystic hygroma, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Increased nuchal translucency, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Chromosomal abnormality",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        In absence of aneuploidy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No visible malformation",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Major cardiac defect",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal or neonatal death",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal pediatric outcome",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: (1) Malone, FD, Ball, RH, Nyberg, DA, et al. First-trimester septated cystic hygroma. Prevalence, natural history, and pediatric outcomes. Obstet Gynecol 2005; 106:288 and (2) Ducarme, G, Graesslin, O, Alanio, E, et al. Increased nuchal translucency and cystic hygroma in the first trimester: prenatal diagnosis and neonatal outcome. Gynecol Obstet Fertil 2005; 33:750.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29979=[""].join("\n");
var outline_f29_17_29979=null;
var title_f29_17_29980="Ophth findings IEM";
var content_f29_17_29980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ophthalmologic findings in inborn errors of metabolism, according to age of onset",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding/Age of onset",
"       </td>",
"       <td class=\"subtitle1\">",
"        Related disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cataract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Birth",
"       </td>",
"       <td>",
"        Lowe syndrome, peroxisomal biogenesis defects, Cockayne syndrome, sorbitol dehydrogenase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 week to 1 month",
"       </td>",
"       <td>",
"        Galactosemia, peripheral epimerase deficiency, 3-phosphoglycerate dehydrogenase deficiency, congenital disorders of glycosylation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 month to 1 year",
"       </td>",
"       <td>",
"        Galactokinase deficiency, galactitol or sorbitol accumulation, sialidosis, mitochondrial disorders, mevalonic aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 to 15 years",
"       </td>",
"       <td>",
"        Dominant hyperferritinemia, Wilson disease, lysinuric protein intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Corneal opacity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 to 12 months",
"       </td>",
"       <td>",
"        Tyrosinosis type II, cystinosis, I-cell disease, mucopolysaccharidosis type I, type VI, steroid sulfatase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 to 6 years",
"       </td>",
"       <td>",
"        Mucopolysaccharidosis type IV, alpha mannosidosis, Tangier disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;6 years",
"       </td>",
"       <td>",
"        Fabry disease, galactosialidosis, Wilson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cherry red spot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neonates",
"       </td>",
"       <td>",
"        GM1 gangliosidosis, galactosialidosis (early infantile form), Niemann-Pick disease type IA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 to 12 months",
"       </td>",
"       <td>",
"        Galactosialidosis (late infantile form), Tay-Sachs disease, Sandhoff disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;6 years",
"       </td>",
"       <td>",
"        Sialidosis type I, galactosialidosis (juvenile form)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Retinitis pigmentosa",
"       </td>",
"       <td>",
"        Abetalipoproteinemia, ceroid lipofuscinosis, peroxisomal disorders, congenital&nbsp;disorders of glycosylation, mitochondrial disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Dislocated lens",
"       </td>",
"       <td>",
"        Homocystinuria, sulfite oxidase deficiency, molybdenum cofactor deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York, 2001. p. 1327.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29980=[""].join("\n");
var outline_f29_17_29980=null;
var title_f29_17_29981="IHC interpretation for mismatch repair genes";
var content_f29_17_29981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretation of immunohistochemistry results for mismatch repair genes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Result",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible interpretation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Explanation/comments",
"       </td>",
"       <td class=\"subtitle1\">",
"        Next steps to consider",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Absence of MLH1 only (rare occurrence)",
"       </td>",
"       <td>",
"        1. MLH1 germline mutation",
"       </td>",
"       <td rowspan=\"2\">",
"        Epigenetic silencing of the MLH1 gene occurs through hypermethylation of the MLH1 promoter",
"       </td>",
"       <td>",
"        MLH1 germline genetic testing or MLH1 methylation +/- BRAF V600E studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Hypermethylation of MLH1 promoter",
"       </td>",
"       <td>",
"        Genetic testing for constitutional MLH1 hypermethylation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Absence of both MLH1 and PMS2",
"       </td>",
"       <td>",
"        1. MLH1 germline mutation",
"       </td>",
"       <td>",
"        MLH1 and PMS2 proteins form a heterodimer. Therefore, PMS2 staining is often absent as a result of a MLH1 mutation",
"       </td>",
"       <td>",
"        MLH1 germline genetic testing or MLH1 methylation +/- BRAF V600E studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Hypermethylation of MLH1 promoter",
"       </td>",
"       <td>",
"        As of 2009, PMS2 germline mutations when tumors show loss of both MLH1 and PMS2 proteins are rare",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        Genetic testing for constitutional MLH1 hypermethylation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Absence of PMS2 only",
"       </td>",
"       <td>",
"        1. PMS2 germline mutation",
"       </td>",
"       <td>",
"        MLH1 protein has dimer partners other than PMS2; therefore, germline mutations in PMS2 may not necessarily cause loss of staining for MLH1",
"       </td>",
"       <td>",
"        PMS2 germline genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. MLH1 germline mutation",
"       </td>",
"       <td>",
"        MLH1 germline mutations have been identified when tumors show loss of staining for PMS2 only",
"        <sup>",
"         [3,4]",
"        </sup>",
"       </td>",
"       <td>",
"        MLH1 germline genetic testing if PMS2 testing does not identify a germline mutation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Absence of MSH2 only (rare occurrence)",
"       </td>",
"       <td>",
"        1. MSH2 germline mutation",
"       </td>",
"       <td>",
"        Strong likelihood of a MSH2 or EPCAM mutation",
"       </td>",
"       <td>",
"        MSH2 germline genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. EPCAM germline mutation",
"       </td>",
"       <td>",
"        Other epigenetic events that result in silencing of MSH2 are undetermined",
"       </td>",
"       <td>",
"        EPCAM deletion studies if MSH2 testing does not identify a germline mutation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Absence of both MSH2 and MSH6",
"       </td>",
"       <td>",
"        1. MSH2 germline mutation",
"       </td>",
"       <td rowspan=\"3\">",
"        MSH2 and MSH6 proteins form a heterodimer; therefore, MSH6 staining is often absent as a result of MSH2 mutation",
"       </td>",
"       <td>",
"        MSH2 germline genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. TACSTD1 germline mutation",
"       </td>",
"       <td rowspan=\"2\">",
"        EPCAM +/- MSH6 germline genetic testing if MSH2 testing does not identify a germline mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. MSH6 mutation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Absence of MSH6 only",
"       </td>",
"       <td>",
"        1. MSH6 germline mutation",
"       </td>",
"       <td rowspan=\"2\">",
"        MSH2 protein has dimer partners other than MSH6; therefore, germline mutations in MSH6 tend to cause loss of staining for MSH6 only",
"       </td>",
"       <td>",
"        MSH6 germline genetic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. MSH2 germline mutation",
"       </td>",
"       <td>",
"        MSH2 germline genetic testing if MSH6 testing does not identify a germline mutation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        All proteins exhibit normal staining",
"       </td>",
"       <td>",
"        1. No Lynch syndrome",
"       </td>",
"       <td rowspan=\"2\">",
"        Normal IHC results do not exclude Lynch syndrome; missense mutation could result in intact, but nonfunctional MMR protein",
"       </td>",
"       <td rowspan=\"2\">",
"        Refer to MSI results +/- family history to guide further evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Possible missense germline mutation in MLH1, MSH2, MSH6 or PMS2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IHC: immunohistochemistry.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Niessen RC, Kleibeuker JH, Westers H, Jager PO, Rozeveld D, Bos KK, et al. (2009). PMS2 involvement in patients suspected of Lynch syndrome. Genes, Chromosomes and Cancer, 48(4), 322-329.",
"       </li>",
"       <li>",
"        Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419-428.",
"       </li>",
"       <li>",
"        De Jong AE, van Puijenbroek M, Hendriks Y, Tops C, Wijnen J, Ausems MG, et al. (2004b). Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clinical Cancer Research, 10(3), 972-980.",
"       </li>",
"       <li>",
"        Zighelboim I, Powell M, Babb S, Whelan A, Schmidt A, Clendenning M, et al. (2009). Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for lynch syndrome. Familial Cancer, 8 (4), 501-504.",
"       </li>",
"      </ol>",
"      Reproduced from: Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for lynch syndrome-a review. J Genet Couns 2011; 20:5, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29981=[""].join("\n");
var outline_f29_17_29981=null;
var title_f29_17_29982="Treatment of pseudogout involving more than two joints";
var content_f29_17_29982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Treatment of pseudogout involving more than two joints",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 359px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Adjust dosage with renal insufficiency.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      NSAID contraindications: renal insufficiency, HF, peptic ulcer disease, hypersensitivity.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Lipsky P. Algorithms for the diagnosis and management of musculoskeletal complaints: A new tool for the primary-care provider. Am J Med 1997; 103:1S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29982=[""].join("\n");
var outline_f29_17_29982=null;
var title_f29_17_29983="Medial epicondylar fracture with entrapment";
var content_f29_17_29983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medial epicondylar fracture with entrapment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Entrapment of fracture fragment in medial epicondylar fracture with posterolateral elbow dislocation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_17_29983=[""].join("\n");
var outline_f29_17_29983=null;
